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Summary 
Aging is the most important risk factor for neurodegenerative dis-
eases associated with pathological protein aggregation such as Alz-
heimer’s disease. Although aging is an important player, it remains 
unknown which molecular changes are relevant for disease initia-
tion. Recently, we and others demonstrated that several hundred 
proteins become highly insoluble with age, in the absence of disease. 
But how these misfolded proteins aggregating with age affect neu-
rodegenerative diseases is not known until today. Importantly, sev-
eral of these aggregation-prone proteins are found as minor compo-
nents in disease-associated aggregates such as amyloid-β plaques or 
neurofibrillary tangles. In this thesis we demonstrate that insoluble 
protein extracts from aged Caenorhabditis elegans or aged mouse 
brains are able to seed amyloid-β aggregation in vitro, whereas pro-
tein aggregates formed during the early stages of life did not initiate 
amyloid-β aggregation. The injection of insoluble protein extracts 
from aged mouse brains into the hippocampus of APP23 transgenic 
mice lead to a formation of some amyloid-β plaques in three out of 
five mice. By mass spectrometry analysis of insoluble protein ex-
tracts from C. elegans we found late-aggregating proteins that were 
previously identified as minor components of amyloid-β plaques 
and neurofibrillary tangles such as 14-3-3, Ubiquitin-like modifier-
activating enzyme 1 and Lamin A/C, highlighting these as strong 
candidates for cross-seeding. Double-transgenic worms overex-
pressing human amyloid-β in the body-wall muscle together with 
PAR-5 (C. elegans homolog of 14-3-3) showed an increase in paraly-
sis, which demonstrates that PAR-5 (14-3-3) could be a potential 
seed for the aggregation of amyloid-β. 
In conclusion, the results presented here show that physiological 
protein aggregation with age might constitute a heterologous seed 
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for disease-associated protein aggregation. To find out why these 
heterologous seeds form with age would have a major impact in 
advancing our understanding of aging and its influence on patho-
physiology. Targeting the seeds before the onset of the disease 
would be an important prevention strategy. 
Recently, widespread protein aggregation as a common feature of 
aging has become an important topic of research. We already 
demonstrated that cross-seeding between different age-dependent  
aggregating proteins is possible in the absence of disease. The inves-
tigation of endogenous age-dependent protein aggregation could 
give insights into molecular and cellular mechanisms that  
regulate protein aggregation and into the effect of protein insolubili-
ty on organisms health. Therefore, we wanted to analyze whether 
rapidly-aggregating proteins can act as harmful seeds for the  
aggregation of other proteins in C. elegans. The goal was to crosslink 
a rapidly-aggregating protein together with its co-aggregating pro-
teins, to purify them and to identify them by mass spectrometry. 
This thesis presents the establishment of a tandem affinity purifica-
tion under denaturing conditions to be used to purify rapidly-
aggregating proteins tagged with a tandem affinity tag.  
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Zusammenfassung 
Alterung ist der wichtigste Risikofaktor für neurodegenerative Er-
krankungen verbunden mit pathologischer Proteinaggregation wie 
zum Beispiel bei der Alzheimer-Erkrankung. Obwohl Alterung ein 
wichtiger Akteur ist bleibt es unbekannt welche molekularen Ver-
änderungen relevant für den Krankheitsbeginn sind. Kürzlich de-
monstrierten wir und andere, dass einige hundert Proteine im Alter, 
in Abwesenheit einer Krankheit, äußerst unlöslich werden. Aber wie 
diese missgefalteten Proteine, die im Alter aggregieren, neurodege-
nerative Erkrankungen beeinflussen, ist bis heute nicht bekannt. 
Wichtig ist, dass einige von diesen aggregations-anfälligen Protei-
nen als nebensächliche Komponenten in krankheitsassoziierten 
Aggregaten, wie Amyloid-β Plaques oder neurofibrillären Bündeln, 
gefunden wurden. In dieser Arbeit demonstrieren wir, dass unlösli-
che Proteinextrakte von gealterten Caenorhabditis elegans oder 
gealterten Maushirnen fähig sind in vitro Amyloid-β Aggregation zu 
"seeden" (säen), wohingegen Proteinaggregate, die sich während 
früher Lebensstadien gebildet haben, keine Amyloid-β Aggregation 
initiierten. Die Injektion von unlöslichen Proteinextrakten gealterter 
Maushirne in den Hippocampus von APP23 transgenen Mäusen 
führte zur Bildung von einigen Amyloid-β Plaques in drei von fünf 
Mäusen. Mit massenspektrometrischer Analyse von unlöslichen 
Proteinextrakten von C. elegans fanden wir spät-aggregierende Pro-
teine die zuvor als nebensächliche Komponenten von Amyloid-β 
Plaques und neurofibrillären Bündeln identifiziert wurden, wie zum 
Beispiel 14-3-3, Ubiquitin-like modifier-activating enzyme 1 und 
Lamin A/C, was diese als starke Kandidaten für "cross-seeding" 
hervorhebt. Doppelt-transgene Würmer, die humanes Amyloid-β im 
sogenannten "body-wall muscle" zusammen mit PAR-5 (C. elegans 
Homolog von 14-3-3) überexprimieren, zeigten eine Erhöhung der 
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Paralyse, was demonstriert, dass PAR-5 (14-3-3) ein potentieller 
"Seed" (Keim) für die Aggregation von Amyloid-β sein könnte.  
Abschließend lässt sich sagen, dass die Ergebnisse, die hier präsen-
tiert werden, zeigen, dass physiologische Proteinaggregation im 
Alter einen heterologen "Seed" für krankheitsassoziierte Proteinag-
gregation bilden könnte. Herauszufinden warum diese heterologen 
"Seeds" sich im Alter bilden würde eine große Auswirkung auf die 
Verbesserung unseres Verständnisses von Alterung und deren Ein-
fluss auf die Pathophysiologie haben. Das Abzielen auf die "Seeds" 
vor dem Beginn der Krankheit wäre eine wichtige Präventionsstra-
tegie.   
Kürzlich wurde die weitverbreitete Proteinaggregation als ein häu-
figes Merkmal von Alterung ein wichtiges Thema in der Forschung. 
Wir haben bereits demonstriert, dass "cross-seeding" zwischen 
verschiedenen altersabhängig aggregierenden Proteinen in Abwe-
senheit einer Krankheit möglich ist. Die Untersuchung von körper-
eigener, altersabhängiger Proteinaggregation könnte Erkenntnisse 
über molekulare und zelluläre Mechanismen bringen, welche die 
Proteinaggregation regulieren und über den Effekt von Proteinun-
löslichkeit auf die Gesundheit des Organismus. Deshalb wollten wir 
untersuchen, ob schnell-aggregierende Proteine als schädliche 
"Seeds" für die Aggregation von anderen Proteinen in C. elegans 
agieren können. Das Ziel war ein schnell-aggregierendes Protein 
zusammen mit seinen co-aggregierenden Proteinen zu vernetzen, 
diese zu reinigen und mittels Massenspektrometrie zu identifizie-
ren. Diese Arbeit präsentiert die Etablierung einer Tandem-
Affinitäts-Reinigung unter denaturierenden Bedingungen um diese 
für die Reinigung schnell-aggregierender Proteine, markiert mit 
einem Tandem-Affinitäts-Marker, zu nutzen.  
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1 Introduction 
This chapter includes parts of the introduction reproduced from: 
Groh N, Bühler A, Huang C, Li KW, van Nierop P, Smit AB, 
Fändrich M, Baumann F and David DC (2017) Age-Dependent 
Protein Aggregation Initiates Amyloid-β Aggregation. Front. 
Aging Neurosci. 9:138. Doi: 10.3389/fnagi.2017.00138 
1.1 Protein folding and misfolding 
To perform their biological function proteins must fold into their 
three-dimensional structure, which is encoded by the amino acid 
sequence. To understand how a protein converts from its un-
folded structure to its thermodynamically favorable native state 
the energy surface or landscape for protein folding has to be 
considered. In the review of (Dobson 2003) it is shown that "the 
surface ‘funnels’ the multitude of denatured conformations to 
the unique native structure". During the folding process the pro-
tein reaches a transition state, which lies on the saddle point of 
the energy surface. In this state a small number of residues have 
formed their native like contacts. Once this so called folding nu-
cleus is generated the topology of the native fold is established 
and the remainder of the structure rapidly condenses (Fersht 
2000).  
Normally, misfolded proteins are ubiquitinated and degraded in 
the cytoplasm by the ubiquitin-proteasome system. However, 
misfolded proteins could also escape the protective mechanisms 
and form aggregates. (Dobson 1999) explains the formation of a 
misfolded globular protein. Under physiological conditions a 
globular protein is folding properly with the polypeptide chain 
and hydrophobic residues hidden in the interior and is secreted 
Introduction 
 
2 
 
from the cell. Under conditions like low pH, heating and in-
creased protein concentration the protein tends to unfold and 
becomes prone to aggregation. In C. elegans it was shown that 
hypertonic stress causes irreversible aggregation of both, endog-
enous and foreign proteins (Burkewitz, Choe, and Strange 2011). 
1.2 Mechanisms to prevent protein aggregation 
In a cell many of the proteins, which are synthesized on ribo-
somes, are intended for secretion to the extracellular space. After 
synthesis these proteins are translocated to the endoplasmic 
reticulum (ER), where they fold correctly with the help of molec-
ular chaperones and folding catalysts before they are secreted 
through the Golgi apparatus (Figure 1.1). 
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Figure 1.1: Protein folding in the endoplasmic reticulum (ER) (Protein 
folding and misfolding, Christopher M. Dobson, Nature 426, 884-890 (18 
December 2003), doi:10.1038/nature02261). 
During aging the regulation of protein homeostasis (proteosta-
sis) is impaired and contributes to the pathological aggregation 
of proteins in neurodegenerative diseases such as Alzheimer’s 
disease. Moreover, the age-related decline in the proteostasis 
network suggests, that misfolding of proteins and their accumu-
lation to aggregates are general consequences of aging as we 
previously showed in C. elegans (David et al. 2010).  
The proteostasis network, which consists of chaperones and 
protein degradation machineries, is required for the surveillance 
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of the proteome, reviewed by (Balchin, Hayer-Hartl, and Hartl 
2016). This network includes molecular chaperones which facili-
tate proper protein folding and refolding as reviewed by (Hartl, 
Bracher, and Hayer-Hartl 2011). Members of the chaperone fam-
ily are known as heat-shock proteins (HSPs), because under 
stress, such as heat stress, protein misfolding increases and the 
HSPs are upregulated. Moreover, the ubiquitin−proteasome sys-
tem (UPS) and autophagy system are responsible for the removal 
of irreversibly misfolded and aggregated proteins (Figure 1.1 
and Figure 1.2). Ubiquitination is a post-translational protein 
modification that governs the degradation of proteins by the 
proteasome. Furthermore, proteins are degraded in lysosomes 
through autophagy. Signaling pathways including the cytosolic 
stress response, which upregulates HSPs during stress (Anckar 
and Sistonen 2011), and the unfolded protein response (UPR) of 
the ER and mitochondria (Schulz and Haynes 2015; Walter and 
Ron 2011) regulate the proteostasis network.  The UPR of the ER 
upregulates ER chaperones, the UPR of mitochondria leads to an 
increased resistance to oxidative damage.  
Introduction 
 
5 
 
 
Figure 1.2: The proteostasis network including 180 chaperone compo-
nents, 600 components of the ubiquitin-proteasome system (UPS) and 30 
components of the autophagy system (Molecular chaperones in protein 
folding and proteostasis, F. Ulrich Hartl, Andreas Bracher & Manajit 
Hayer-Hartl, Nature 475, 324–332 (21 July 2011), 
doi:10.1038/nature10317). 
With age the chaperone function and availability is reduced as 
reviewed by (Kaushik and Cuervo 2015). Moreover, age-related 
modifications on proteins interfere with the target-recognition 
ability of chaperones. Additionally, autophagy and proteasome 
activity decrease with age. In C. elegans the ectopic expression of 
RPN-6, a 19S proteasome subunit, leads to proteotoxic stress 
resistance and extends lifespan (Vilchez et al. 2012). It was also 
shown that overexpression of the proteasome subunit 20S in-
creases lifespan and resistance to stress (Chondrogianni et al. 
2015). Furthermore, the overexpression of the autophagy stimu-
lator HLH-30 extends lifespan in C. elegans (Lapierre et al. 2013).  
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1.3 Protein aggregation in neurodegenerative diseases 
A variety of neurodegenerative diseases are associated with the 
misfolding and aggregation of specific proteins. For example, in 
Alzheimer’s disease (AD), amyloid-β (Aβ) peptides and tau pro-
teins aggregate and ultimately form the characteristic pathologi-
cal hallmarks: amyloid plaques and neurofibrillary tangles 
(NTFs) respectively. For Aβ and tau (and also other amyloido-
genic proteins) it has been reported that the more toxic species 
might be small intermediates in the aggregation process, the 
soluble oligomers (Haass and Selkoe 2007; Spires-Jones et al. 
2011). As reviewed by (Haass and Selkoe 2007) some oligomeric 
species of Aβ are small and soluble enough to diffuse through the 
brain parenchyma and affect synaptic structure, function and 
neuronal survival, whereas the insoluble inclusions might func-
tion as reservoir for soluble oligomers. The amyloid cascade 
hypothesis, reviewed by (Haass and Selkoe 2007), explains how 
Aβ accumulation could result to AD. In the first part of the cas-
cade an increase in the Aβ42/Aβ40 ratio enhances oligomeriza-
tion of the highly amyloidogenic Aβ42 isoform. The increase of 
the ratio can be augmented by mutations in β-amyloid precursor 
protein (APP), presenilin-1 (PS-1) and presenilin-2 (PS-2) that 
cause familial forms of AD (Scheuner et al. 1996; Suzuki et al. 
1994). APP is a single-transmembrane, receptor-like protein that 
is processed by β-site APP-cleaving enzyme (BACE) and the γ-
secretase complex (including PS-1 and PS-2). The γ-secretase 
cleavage-sites on APP are variable and can occur after amino 
acids 38, 40 and 42 leading to the liberation of different forms of 
Aβ into the extracellular space.  
In AD and other tauopathies NFTs are formed by intracellular 
accumulations of hyperphosphorylated tau, reviewed by (Kuret 
et al. 2005). An ongoing question is whether the tangles are the 
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toxic species in the brain, but that tau dysfunction can lead to 
neurodegeneration is generally accepted. It has been shown that 
the expression of an aggregation-prone tau construct is associat-
ed with cell death in cultured cells (Khlistunova et al. 2006; 
Wang et al. 2007). 
In general, knowledge of the nature of aggregate pathogenicity 
would be important to identify targets for therapeutic interven-
tions. (Bucciantini et al. 2002) demonstrated that aggregates of 
two different non-disease-related proteins can be inherently 
cytotoxic suggesting toxicity of aggregated species could be a 
general phenomenon. The data support the assumption that non-
fibrillar aggregates, that precede formation of mature amyloid 
fibrils, may be the primary toxic species. (Olzscha et al. 2011) 
generated artificial proteins with β-sheet structures (so called β 
proteins) that lead to the formation of amyloid-like aggregates 
and toxicity in HEK293T cells. They showed that the protein with 
the highest toxicity has the tendency to form prefibrillar aggre-
gates in vitro. Moreover, the β proteins co-aggregate with two 
types of endogenous aggregation-prone proteins with specific 
sequence features. One group includes the pre-existing proteins 
that are enriched in intrinsically unstructured regions and are 
prone to aggregate even in their post-folding state. The other 
group, the newly synthesized proteins, contain large or mul-
tidomain proteins which are prone to aggregate during and 
shortly after synthesis.  
An important and currently understudied question is how aging 
influences protein aggregation in neurodegeneration. Recently, 
physiological protein insolubility in the context of aging has be-
come an important topic of research (David 2012; Partridge 
2011). Indeed, numerous publications demonstrate that protein 
aggregation is not restricted to disease but a normal conse-
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quence and possibly cause of aging (Ayyadevara, Mercanti, et al. 
2016; David et al. 2010; Demontis and Perrimon 2010; Lechler et 
al. 2017; Ottis et al. 2013; Peters et al. 2012; Reis-Rodrigues et al. 
2012; Tanase et al. 2016; Walther et al. 2015). To investigate 
endogenous age-dependent protein aggregation could give in-
sights into molecular and cellular mechanisms that regulate pro-
tein aggregation and into the effect of protein insolubility on 
organisms health, without the need to ectopically express human 
disease-associated proteins in model organisms.  
Until now it remains unclear whether and how age-dependent 
protein aggregation and disease-associated protein aggregation 
influence each other. One possibility is that age-dependent ag-
gregates indirectly accelerate disease-associated protein aggre-
gation by stressing the cell and/or titrating away anti-
aggregation factors. Another possibility is a direct interaction 
whereby disease-associated proteins and age-dependent aggre-
gation-prone proteins co-aggregate. In support of this latter hy-
pothesis, proteins prone to aggregate during normal aging are 
significantly overrepresented as minor protein components in 
amyloid plaques and NFTs (Ayyadevara, Balasubramaniam, 
Parcon, et al. 2016; David et al. 2010). Recent research reveals 
that the sequestration of these age-dependent aggregation-prone 
proteins in the disease aggregates is a source of toxicity 
(Ayyadevara, Balasubramaniam, Parcon, et al. 2016).  
1.4 Amyloids and seeding mechanisms 
In neurodegenerative diseases specific proteins are aggregating 
in an amyloid conformation. One of the most known amyloids is 
amyloid-β (Aβ) peptide which aggregates in Alzheimer’s disease. 
The term amyloid describes multimeric proteinaceous assem-
blies with a cross-β quaternary structure. Proteins in the amy-
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loid state form elongated fibrils which are unbranched and can 
be found in vivo (Eisenberg and Jucker 2012). In all fibrils β-
sheets are arranged in parallel to the fibril axis with the β-
strands perpendicular to the axis. This formation is stabilized by 
hydrogen bonds. To prove whether an aggregated protein is in 
an amyloid state, usually the dye Congo red is used. Congo red 
binding is monitored by a red shift in the light absorption and a 
characteristic green birefringence under crossed polarization. 
Moreover, the cross-β structure is detected in X-ray diffraction 
and the typical morphology is analysed by electron microscopy. 
As reviewed by (Eisenberg and Jucker 2012) amyloid formation 
occurs because the free energy of it is highly favourable. Another 
reason is an abnormally high protein concentration (Balch et al. 
2008). 
In recent years, understanding the initiation and spread of hall-
mark protein aggregates such as Aβ or tau has become a central 
area of investigation (Jucker and Walker 2011). The current 
model stipulates that aggregation in disease is initiated by a 
protein seed that forms a template for further protein aggrega-
tion (Jucker and Walker 2013). In detail, an amyloid seed is 
formed by the aggregation of native proteins through intermedi-
ate states during a slow nucleation phase. Then monomers and 
oligomeric structures are bonded to the end of the initial amy-
loid seed which leads to a growing fibril that can break during 
the rapid growth phase. This results to the generation and 
spreading of new seeds. 
In transgenic models for Aß amyloidosis, intracerebral injections 
of brain extracts containing minute amounts of aggregated Aß 
seeds are sufficient to instigate the formation of Aß plaques 
(Kane et al. 2000; Meyer-Luehmann et al. 2006). This process is 
called homologous seeding (Figure 1.3A). However, whether 
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misfolded proteins aggregating with age can form heterologous 
seeds that initiate Aβ aggregation (Figure 1.3A) has not been 
investigated. Although current research focuses on homologous 
seeding, there are a few examples of cross-seeding (or heterolo-
gous seeding), mostly between different disease-aggregating 
proteins (Morales, Moreno-Gonzalez, and Soto 2013). For in-
stance, Aβ is a potent seed for the aggregation of human islet 
amyloid polypeptide involved in type II diabetes (O'Nuallain et 
al. 2004; Oskarsson et al. 2015); Aβ and prion protein PrPSc 
cross-seed each other and accelerate neuropathology (Morales et 
al. 2010); and both α-synuclein and Aβ co-aggregate with tau and 
enhance tau pathology in vivo (Guo et al. 2013; Vasconcelos et al. 
2016). Finally, we recently showed that cross-seeding between 
different age-dependent aggregating proteins is possible in the 
absence of disease (Lechler et al. 2017). Until today little is 
known about heterologous seeding of disease-aggregating pro-
teins by non-disease aggregating proteins. One example is ace-
tylcholinesterase, which is also found in Aß plaques (Alvarez et 
al. 1998; Jean et al. 2007).  
The in vitro Aβ seeding assay or FRANK assay (Fibrillisation of 
Recombinant Aβ Nucleation Kinetic) (Nagarathinam et al. 2013) 
has been used to analyse if brain-derived Aβ is able to induce the 
aggregation of monomeric recombinant Aβ. In general, over time 
Aβ fibrils are formed, detected by the increase in fluorescence of 
the amyloid dye Thioflavin T (ThT) (Figure 1.3B, red line). The 
time that is needed to form initial fibril seeds is called the lag 
time. If brain-derived Aβ is added, the lag time is reduced by the 
initiation and acceleration of Aβ aggregates (Figure 1.3B, blue 
line). The investigation whether extracts containing non-disease 
aggregating proteins (age-dependent protein aggregates) are 
also able to reduce the lag time has not been done so far.  
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Figure 1.3: Schematic representation of homologous and heterologous Aβ 
seeding and determination of lag times (reproduced from Frontiers arti-
cle).  
A Homologous seeding (upper part): Aβ monomers very slowly accumu-
late to metastable intermediate oligomers which act in a succeeding step 
as a seed for fast Aβ accumulation. Initial seed formation critically de-
pends on exceeding a minimal local concentration of Aβ. This process 
leads to stable Aβ aggregate formation (fibril formation) which can break 
and serve as new seeds for further Aβ aggregation.  
Heterologous seeding (lower part): Hypothetically during aging, Aβ mon-
omers and age-dependent protein aggregates accumulate and build to-
gether an initial seed which leads to a faster accumulation of Aβ aggre-
gates bypassing the slow buildup of homologous seeds from monomeric 
Aβ. This might be even more important when Aβ concentration never 
reaches the minimal local concentration for homologous seed formation. 
B During the FRANK assay (Fibrillisation of Recombinant Aβ Nucleation 
Kinetic) protein extracts are measured in the presence of Thioflavin T 
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(ThT) and recombinant Aβ1-40. Aβ fibrils, which are detected by the in-
corporation of ThT, are formed after initial fibril seeds develop. After this 
the ThT fluorescence increases rapidly until a maximum is reached (red 
line). The time that is needed to form initial seeds is called the lag time. 
Brain derived Aβ (or hypothetically age-dependent protein aggregates) 
reduce the lag time by initiating and accelerating Aβ aggregation (blue 
line). 
1.5 Caenorhabditis elegans as a model system  
The nematode C. elegans was developed as a model system to 
study developmental biology and neurobiology by Sydney Bren-
ner. As described by (Corsi, Wightman, and Chalfie 2015) the 
small size (length of adults amounts to 1 mm), the transparent 
body, the simple body plan including pharynx, intestine, gonads 
and muscles and the well-annotated genome are reasons why it 
is a useful model system. Moreover, C. elegans has a rapid lifecy-
cle: after hatching the worms develop from four larval stages (L1 
to L4) to adults that lay eggs in approximately 55 hours at 20°C. 
They exist primarily as a self-fertilizing hermaphrodite, but also 
males arise at a low frequency (<0.2%) (Corsi, Wightman, and 
Chalfie 2015). The free-living nematode can be found worldwide. 
In the laboratory, they live on agar plates or in liquid culture and 
are fed with bacteria (E. coli). Their nervous system is composed 
of exactly 302 neurons. As a model system to study aging and 
age-related diseases, C. elegans has a lot of advantages: First of 
all, the worms have a short lifespan (about 17 days for wild-type 
worms). Moreover, different longevity pathways are known. 
Additionally, specific genes can be easily knocked down by RNA 
interference (RNAi). It was shown by (Fire et al. 1998) that injec-
tion of double stranded RNA (dsRNA) into worms resulted to 
degradation of the corresponding messenger RNA (mRNA) and 
therefore to potent interference. Moreover, feeding worms with 
bacteria expressing dsRNA of the gene of interest induces RNAi 
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response, demonstrated by (Tabara, Grishok, and Mello 1998; 
Timmons and Fire 1998). Because the complete genomic se-
quence of C. elegans is available, RNAi is a useful technique to 
study gene function. Another advantage of using C. elegans as an 
in vivo system is the possibility to overexpress toxic proteins 
prone to pathological misfolding. (Teschendorf and Link 2009) 
reviewed that the expression of specific human proteins linked 
to neurodegeneration leads to cellular toxicity in worms. One 
example for using C. elegans as transgenic model for neuro-
degenerative diseases is the expression of human Aβ in the 
body-wall muscle under the unc-54 promoter (Link 1995). The 
group of Christopher Link discovered that Aβ accumulates in 
muscle cells forming amyloid deposits. Later (McColl et al. 2012) 
generated a model where Aβ aggregates in muscle cells and re-
sults in temperature induced age-progressive paralysis. 
1.6 Objectives 
1.6.1 Identifying age-dependent heterologous seeds for 
amyloid-β aggregation 
A variety of neurodegenerative diseases are associated with the 
misfolding and aggregation of specific proteins. To understand 
the initiation and spread of hallmark protein aggregates such as 
Aβ or tau has become a central area of investigation. Recently, a 
model was published stipulating that aggregation in disease is 
initiated by a protein seed that forms a template for further pro-
tein aggregation. Targeting the seeds before the onset of the 
disease would be an important therapeutic strategy. The thesis 
presented here describes the investigation whether endogenous 
proteins, that aggregate with age, can seed the aggregation of Aβ. 
To address our hypothesis, we wanted to examine detergent-
insoluble protein extracts from young and aged wild-type 
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C. elegans and young and aged wildtype mouse brains. To ana-
lyse Aβ aggregation in the presence of the insoluble fraction, we 
wanted to use an in vitro seeding assay (FRANK assay, Fibrillisa-
tion of Recombinant Aβ Nucleation Kinetic). Quantitative mass 
spectrometry with the insoluble proteome of C. elegans and 
mouse brains from different ages should be performed to identi-
fy changes in aggregation with age. With the comparison of ear-
ly- and late-aggregating proteins with the highest change in ag-
gregation with age in C. elegans with minor components of Aβ 
plaques and neurofibrillary tangles we wanted to identify poten-
tial candidates for seeding Aβ.  
1.6.2 Investigation whether rapidly-aggregating proteins 
seed the aggregation of other proteins 
To characterize endogenous age-dependent protein aggregation 
could help to understand the molecular and cellular mechanisms 
that regulate protein aggregation. Moreover, the characterization 
could give insights into the effect of protein insolubility on or-
ganisms health. Therefore, the goal was to investigate whether 
rapidly-aggregating proteins can act as harmful seeds for the 
aggregation of other proteins in C. elegans. An early-aggregating 
protein, identified in the first part of the thesis, should be chemi-
cally crosslinked together with its co-aggregating proteins. Next, 
they should be purified and identified by mass spectrometry.  
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2 Material and Methods 
2.1 Identifying age-dependent heterologous seeds for 
amyloid-β aggregation 
This chapter includes parts of the material and methods repro-
duced from: 
Groh N, Bühler A, Huang C, Li KW, van Nierop P, Smit AB, 
Fändrich M, Baumann F and David DC (2017) Age-Dependent 
Protein Aggregation Initiates Amyloid-β Aggregation. Front. 
Aging Neurosci. 9:138. Doi: 10.3389/fnagi.2017.00138 
2.1.1 C. elegans mutant and transgenics  
Table 2.1: C. elegans mutant and transgenic strains used in this study. 
Strain name Genotype 
CF2253 gon-2(q388)I 
GMC101 
dvIs100[unc-54p::A-beta-1-42::unc-54 3'-UTR +  
mtl-2p::GFP] 
UE50 oaSi10[par-5p::GFP::par-5::par-5 3'UTR + unc-119(+)] 
DCD296 
(GMC101;UE50) 
dvIs100[unc-54p::A-beta-1-42::unc-54 3'-UTR + mtl-
2p::GFP]; oaSi10[par-5p::GFP::par-5::par-5 3'UTR + 
unc-119(+)] 
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2.1.2 Bacterial strains 
Table 2.2: Bacterial strains used in this study as food source for C. elegans. 
Strain name Description 
OP50 Escherichia coli (E. coli) strain 
OP50-1 OP50 with streptomycin resistance 
 
2.1.3 Mouse strains 
Wild-type C57BL/6J (WT) and transgenic APP23 mice 
(Sturchler-Pierrat et al. 1997)  were bred and maintained under 
pathogen-free conditions at the Hertie Institute for Clinical Brain 
Research, Tübingen, controlled by Dr. Frank Baumann. All stud-
ies were performed in accordance with German animal welfare 
legislation and with approval from the Ethical Commission for 
animal experimentation of Tübingen, Germany. Age and sex of 
mice used for the FRANK assay (Fibrillization of Recombinant Aβ 
Nucleation Kinetic) and mass spectrometry are listed in Table 
2.3. 
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Table 2.3: Mice used for FRANK assay (Fibrillization of Recombinant Aβ 
Nucleation Kinetic)* and mass spectrometry# (mainly reproduced from 
Frontiers article). 
Number Sex Age (months) 
7519* male 2 
8418* female 2 
8419* female 2 
8628*# male 3 
8629*# male 3 
8916* female 2 
8951# female 2 
8070# female 20 
8036* female 20 
7830*# male 18 
7831*# male 18 
524* female 18 
503* female 19 
1736* female 20 
7755* female 25 
7718* male 27 
7601* female 28 
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11523* (APP23) male 20 
 
2.1.4 Growing and Maintenance of C. elegans  
Hermaphrodites were grown on Nematode Growth (NG) plates 
(preparation of NG plates is described at 
http://www.wormbook.org/chapters/www_strainmaintain/stra
inmaintain.html) containing the bacterial (E. coli) strain OP50 at 
either 15°C, 20°C or 25°C. Stock plates were kept at 15°C. 
Males were grown on empty NG plates with a low amount of 
OP50 at 15°C or 20°C. Once per week (if incubated at 20°C every 
four days) 12 males were mated with three L4s from a stock of 
the respective strain. To generate new males of a transgenic 
strain with a fluorescent marker three L4s of the respective 
strain were first crossed with 12 N2 males. To continue, three 
fluorescent L4s were picked from a stock of the transgenic strain 
and crossed with 12 fluorescent males from the last mating 
plate. The last step was repeated three times before the males 
were used for example for a cross with another strain.   
2.1.5 Strain generation 
To generate the double transgenic strain DCD296 overexpress-
ing Aβ and PAR-5, GMC101 males were generated by crossing N2 
males to GMC101 hermaphrodites as described at 2.1.4 and by 
mating the GMC101 males into UE50 hermaphrodites (as de-
scribed at (Fay 2013), http://www.wormbook.org). 
2.1.6 C. elegans liquid culture 
To obtain large aged-synchronized populations of C. elegans, 
temperature induced sterile gon-2 mutants (CF2253) were used. 
The whole procedure was carried out independently four times 
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to collect four biological replicates with four time points, respec-
tively. The worms were collected at day 2 (reproductive ani-
mals), day 6 (at the end of reproduction in wild-type animals), 
day 10 (around 30% of the population has died) and day 14 
(around 50% of the population has died). Age is defined by the 
number of days of adulthood starting from the last larval stage 
L4. 
2.1.6.1 Propagation of gon-2 mutants to collect the parental 
generation for the temperature shift 
As food source the E. coli OP50-1 strain, which has a streptomy-
cin resistance, was streaked out onto a Lysogeny Browth (LB) 
plate with 50 µg/mL streptomycin and incubated over night at 
37°C (as described at http://www.wormbook.org/chapters/ 
www_strainmaintain/ strainmaintain.html). 200 mL LB medium 
with 50 µg/mL streptomycin were inoculated with one clone 
OP50-1 and incubated over night at 37°C. 15 High Growth Medi-
um (HGM) plates (diameter 9 cm) with 50 µg/mL streptomycin 
(later called HGM/streptomycin plates) were inoculated with 
0.5 mL OP50-1 which was distributed with a spatula. Gon-2(-) 
animals (not starved for the last two generations) were chunked 
onto the 15 HGM/streptomycin plates seeded with OP50-1 and 
maintained at 20°C until plates were confluent with adults and 
some OP50-1 was still available. Confluent plates were bleached 
(as described at (Sulston 1988)), eggs were collected in 15 mL-
tubes with M9 solution (85 mM NaCl, 42 mM Na2HPO4 · 7 H2O, 
22 mM KH2PO4) and placed on a nutating mixer overnight at 
20°C. Hatched L1s were washed with M9 as follows: L1s were 
centrifuged at 3000 x g for 30 s, supernatants were discarded 
and the tubes were filled up to 15 mL mark with M9. This step 
was repeated twice. The tubes with the resulting worm pellets 
were filled up to 15 mL mark with M9. The total number of L1s 
Material and Methods 
 
20 
 
was evaluated under a dissection microscope by counting the 
L1s present in 2 µL drops placed on a non-seeded NG plate. The 
numbers obtained from at least nine drops were averaged and 
6500 L1s were added on one HGM/streptomycin plate, which 
was seeded before with OP50-1 as described above. In total 60 
HGM/streptomycin plates were prepared as described and the 
worms were grown at 20°C until L4 stage. 
2.1.6.2 Temperature shift to obtain gonad-less animals for the 
liquid culture 
At L4 stage, the worms were shifted to 25°C until they started to 
lay eggs and L1s were hatching. To separate the fragile eggs and 
L1s from the adults and to collect them, sedimentation was used. 
The plates were washed with M9 by using 5 mL M9 per five 
plates. Worms were transferred into 50 mL-tubes. Tubes were 
filled up to 45 mL mark with M9, the adults were sedimented for 
10 min, each supernatant was collected in a 50 mL-tube and the 
step was repeated with the pellets. The supernatants, that con-
tained eggs and L1s, were centrifuged at 3000 x g for 1 min, the 
L1s were sedimented for 10 min and the supernatants were 
removed until 15 mL were left. The tubes containing eggs and 
L1s were placed on a nutating mixer over night at 25°C. 
2.1.6.3 Collection of OP50-1 culture as food source 
8 L LB medium with a final concentration of 50 µg/mL strepto-
mycin were inoculated with 24 mL OP50-1 from a 200 mL-
overnight-culture and incubated at 37°C overnight at 180 rpm. 
The OP50-1 culture was harvested by centrifugation at 6700 x g 
for 10 min at 4°C. The supernatant was removed and the pellet 
was resuspended in 120 mL ice-cold S basal (100 mM NaCl, 
50 mM Potassium phosphate pH 6).  
Material and Methods 
 
21 
 
2.1.6.4 Liquid cultures to collect gon-2(-) mutants at day 2, day 6, 
day 10 and day 14 
Per condition (four in total), 200 mL S basal was added in a 
Fernbach culture flask (capacity 2,800 mL). For a final culture 
volume of 300 mL the following ingredients were added: 10 mM 
Potassium citrate, pH 6, 3 mL Trace metals solution (5 mM Eth-
ylenediaminetetraacetic acid (EDTA), 2.5 mM FeSO4, 1 mM 
MnCl2, 1 mM ZnSO4, 0.1 mM CuSO4), 3 mM MgSO4, 3 mM CaCl2, 
100 ng/mL carbendazim, 5 µg/mL cholesterole and 50 µg/mL 
streptomycin.  
The L1s obtained as described at 2.1.6.2 were transferred to 
15 mL-tubes and centrifuged at 1900 x g for 3 min. The superna-
tant was removed and the L1s per 2 µL were counted. As men-
tioned above, four biological replicates with four time points 
respectively were prepared. The total numbers of worms grown 
in the four liquid cultures for each replicate are shown in Table 
2.4. The following describes the procedure for replicate number 
four as an example for all replicates: In total 695,000 worms 
were needed to divide them to four flasks. OP50-1 was added 
proportionally to the number of worms: Out of 120 mL total 
OP50-1, each time 20 mL were added to the flask for the day 2 
and day 6 worm collections, 30 mL to the flask for the day 10 
worm collection and 35 mL to the flask for the day 14 worm 
collection. The following amount of worms was added to the 
following worm collection: 170,000 worms to day 2, 150,000 
worms to day 6 and day 10 and 225,000 worms to day 14. Each 
worm culture was completed with S basal to bring the total vol-
ume to 300 mL and incubated at 25°C and 150 rpm. An aliquot 
from each liquid culture was periodically collected and placed on 
a glass slide. Using a dissection microscope, the bacterial food 
level in each culture was checked especially during the growth 
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phase. In advance a 4 L OP50-1 culture was prepared and har-
vested as described at 2.1.6.3 and a part of it was added to the 
cultures if necessary. Additionally, the sterility of the animals 
was analyzed. The majority of animals did not have a gonad, no 
animals with eggs were observed.  
Table 2.4: Amount of worms grown in liquid cultures for different days for 
each biological replicate (reproduced from Frontiers article). 
Replicate Day 2 Day 6 Day 10 Day 14 
1  100,000 100,000 150,000 200,000 
2  150,000 150,000 200,000 350,000 
3  250,000 150,000 175,000 300,000 
4  170,000 150,000 150,000 225,000 
 
2.1.6.5 Collection of gon-2(-) mutants by sucrose separation 
At day 2, day 6, day 10 and day 14 worms were collected and 
removed from bacteria and dead worms by sucrose separation. 
The worm culture from one flask was added into a separatory 
funnel and the worms were sedimented for 10 min at room tem-
perature. The worms were collected in one 50 mL-tube. The 
worm pellet was transferred to two 15 mL-tubes and centrifuged 
at 1900 x g for 5 min at room temperature. To wash the worms, 
the supernatants were removed and the tubes were filled up to 
15 mL mark with M9. The centrifugation was repeated. Finally, 
the worms were transferred to two 50 mL-tubes and filled up to 
20 mL total volume with ice-cold M9. To remove bacteria and 
dead worms, the two 20 mL diluted worm pellets were added to 
two 50 mL-tubes filled with 20 mL ice-cold 60% sucrose and 
centrifuged at 2700 x g for 5 min at 4°C (acceleration 9 and de-
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celeration 7). The top worm layers were taken and added direct-
ly into 37 mL of M9 with 0.01% Triton X 100 (AppliChem) 
(called M9+triton) (3 tubes per sucrose tube) prepared on ice. 
After centrifugation at 2700 x g for 3 min at 4°C (acceleration 9 
and deceleration 7), the supernatants were removed and the 
pellets were divided into four 15 mL-tubes. The worms were 
washed as follows: The tubes were filled up to 15 mL mark with 
ice-cold M9+triton and centrifuged at 1900 x g for 1 min at room 
temperature. The supernatants were removed and the pellets 
were again filled up to 15 mL mark with ice-cold M9+triton and 
centrifuged. The last step was repeated with ice-cold M9. The 
four tubes were combined to two tubes, filled up with M9 at 
room temperature to a total volume of 4 mL in the 15 mL-tubes 
and rotated on a nutating mixer at 25 °C for 40 min. This helped 
the worms to digest any residual bacteria in the gut. The worms 
were analyzed with a dissection microscope to control that there 
were no dead ones. The worms were washed twice with ice-cold 
M9+triton and twice with M9 as described before. At the end the 
worms were transferred to one tube and washed once in the 
Reassembly (RAB) high-salt extraction buffer without inhibitors 
(0.1 M 4-Morpholineethanesulfonic acid (MES), 1 mM Eth-
yleneglycoltetraacetic acid (EGTA), 0.1 mM Ethylenediaminetet-
raacetic acid (EDTA), 0.5 mM MgSO4, 0.75 M NaCl, 0.02 M Sodi-
um fluoride (NaF)) before collection. The supernatant was re-
moved until there was no liquid on top of the worm pellet. The 
volume of the worm pellet was estimated and an identical vol-
ume of RAB with inhibitors (2x Complete Protease Inhibitor 
Cocktail, Roche) was added. Using a Pasteur pipette, worms were 
drawn up and slowly dripped into a 50 mL-tube half filled with 
liquid nitrogen placed in dry ice. Frozen worms were stored at  
-80 °C until further processing. 
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2.1.6.6 Disruption of animals collected by sucrose separation 
The frozen worm pellet of one day was transferred to a mortar 
that was pre-cooled with liquid nitrogen on dry ice and the pellet 
was ground for 2.5 min. Liquid nitrogen was added to the pow-
der to cool it down again and the powder was ground for anoth-
er 2.5 min. With the dissection microscope it was analyzed that 
the worm bodies were broken. This procedure was repeated for 
each day and each replicate. The powder was stored at -80 °C. 
2.1.6.7 Liquid culture with C. elegans transgenic strain overex-
pressing Aβ (GMC101) 
To obtain a large population of the C. elegans transgenic strain 
GMC101 which overexpresses Aβ as positive control for the 
FRANK assay, the same protocol as described above was used 
with the following changes: Worms were grown on 15 HGM 
plates seeded with OP50 and bleached when plates were conflu-
ent. After an L1 arrest overnight at 20°C, 150,000 worms were 
grown in liquid culture with OP50 at 20°C until day 1 and shifted 
to 25°C to induce paralysis (McColl et al. 2012). At day 2 worms 
were collected and disrupted as described.  
2.1.7 Insoluble protein extraction for mass spectrometry 
and FRANK assay with C. elegans 
To isolate Sodium dodecyl sulfate (SDS)-insoluble proteins for 
mass spectrometry analysis and the FRANK assay, a sequential 
extraction was performed with each time point and each repli-
cate. All centrifugation steps were performed at 18,400 x g for 
20 min at 4°C. The buffers, that were used for the extraction, are 
shown in Table 2.5. For mass spectrometry analysis, two times 
350 mg ground worms per time point were weighed out on dry 
ice. To remove the high-salt soluble proteins two volumes of RAB 
with inhibitors, 1 mM Phenylmethylsulfonyl fluoride (PMSF), 
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200 U/mL DNaseI (Roche) and 100 µg/mL RNaseA (Promega) 
per weight (700 µL total) were added to each tube and the pow-
der was solubilized on ice. The suspension was drawn up into a 
1 mL syringe (gray needle, 27 G x ½ ", 0.4 mm x 13 mm) 15 times 
and incubated on ice for 10 min. For the FRANK assay, 50 mg 
ground worms (gon-2 mutants or Aβ overexpressing transgen-
ics) per time point were solubilized in 200 µL RAB buffer with 
inhibitors, PMSF, DNaseI and RNaseA. After centrifugation the 
supernatant containing high-salt soluble proteins was collected 
and the fat layer was discarded. After dialysis against PBS, these 
high-salt soluble proteins of gon-2 mutants were used as soluble 
fraction in the FRANK assay. To remove lipids, the pellet was 
resuspended in two volumes of RAB with inhibitors (without 
DNaseI and RNaseA) containing 1 M sucrose (respectively 
200 µL for the FRANK assay extraction). The suspension was 
drawn up into a syringe 10 times and incubated on ice for 5 min. 
After centrifugation all supernatant and lipids were removed and 
discarded. To remove SDS-soluble proteins, the pellet was resus-
pended in two volumes of Radioimmunoprecipitation assay (RI-
PA) buffer (respectively 200 µL for the FRANK assay extraction) 
(50 mM Tris(hydroxymethyl)aminomethane (Tris) pH 8, 
150 mM NaCl, 5 mM EDTA, 0.5% SDS, 0.5% Sodium deoxycholate 
(SDO), 1% Nonidet P40 (NP40) (Applichem), 1 mM PMSF, 1x 
Complete Protease Inhibitor Cocktail (Roche)). The suspension 
was drawn up into a syringe 10 times and incubated for 10 min 
on ice. After centrifugation the supernatant containing SDS-
soluble proteins was collected. The two samples of each condi-
tion were pooled together after solubilizing each pellet with 
500 µL RIPA buffer (for the FRANK assay the pellet from one 
condition was solved with 200 µL RIPA buffer). The suspension 
was drawn up into a syringe 10 times and centrifuged. All super-
natant was removed and discarded. The final pellet containing 
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highly insoluble proteins was resuspended in 400 µL 70% formic 
acid for mass spectrometry. The suspension was drawn up into a 
syringe 20 times, incubated for 20 min on ice and centrifuged at 
50,000 x g for 20 min at 4°C, to remove worm cuticle debris. For 
the FRANK assay, the final pellet was resuspended in 100 µL PBS 
and centrifuged at 3,000 x g for 5 min at 4°C to remove the worm 
cuticle. The supernatant, that contains highly insoluble proteins, 
was collected.  
2.1.8 Quick protein extraction for western blot analysis 
To isolate detergent-soluble and -insoluble proteins for western 
blot analysis, a simplified protocol was used where 50 mg of 
ground animals in RAB buffer with inhibitors were directly re-
suspended in 150 µL RIPA buffer and the suspension was drawn 
up into a 1 mL syringe 10 times. SDS-insoluble proteins were 
isolated by resuspension in RIPA buffer and centrifugation at 
18,400 x g for 20 min at 4°C.  The pellet was washed once in 
100 µL RIPA buffer. Final pellets containing insoluble proteins 
were recovered in 75 µL 8 M Urea, 2% SDS, 50 mM Dithiothreitol 
(DTT), 50 mM Tris pH 8 at room temperature. 
2.1.9 Mouse brain preparation and insoluble protein ex-
traction for mass spectrometry and FRANK assay 
Brains from wild-type mice (Table 2.3) were divided into both 
hemispheres after the cerebellum had been removed by Dr. 
Frank Baumann at the Hertie Institute for Clinical Brain Re-
search, Tübingen. The same was done with the mouse brain from 
a transgenic APP23 mouse (20 months) for the FRANK assay. 
Two volumes per weight RAB buffer with inhibitors, PMSF, 
DNaseI and RNaseA (see above and Table 2.5) were added per 
hemisphere. Each hemisphere was homogenized with the Precel-
lys Ceramic Beads Kit (Cayman Chemical) for two times 10 s 
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with 10 s pause in between. The homogenate was transferred 
into a new tube and processed as described for C. elegans. During 
each extraction step, two volumes buffer per weight were used. 
High-salt soluble proteins were removed by centrifugation at 
18,400 x g for 20 min at 4°C. After dialysis against PBS, these 
high-salt soluble proteins were used as soluble fraction in the 
FRANK assay. Insoluble proteins were isolated as was performed 
with C. elegans, the final pellet containing highly insoluble pro-
teins was resuspended in 200 µL 70% formic acid for mass spec-
trometry. For the FRANK assay the resulting pellet was resus-
pended in 200 µL PBS. The sample was centrifuged at 3,000 x g 
for 5 min at 4°C and the supernatant containing the detergent-
insoluble proteins was used for the FRANK assay.    
Table 2.5: Buffers for insoluble protein extraction.   
Buffer Components 
RAB (with 
inhibitors, 
PMSF, DNaseI, 
RNaseA) 
0.1 M MES, 1 mM EGTA, 0.1 mM EDTA, 0.5 mM 
MgSO4, 0.75 M NaCl, 0.02 M NaF,  
2x Complete Protease Inhibitor Cocktail (Roche), 
1 mM PMSF, 200 U/mL DNaseI (Roche), 100 µg/mL 
RNaseA (Promega) 
RIPA 
50 mM Tris pH 8, 150 mM NaCl, 5 mM EDTA, 0.5% 
SDS, 0.5% SDO, 1% NP40 (Applichem), 1 mM PMSF, 
1x Complete Protease Inhibitor Cocktail (Roche) 
Formic acid 70% in ddH2O 
Urea/SDS 8 M Urea, 2% SDS, 50 mM DTT, 50 mM Tris pH 8 
 
2.1.10 Gel electrophoresis and Western blotting  
Proteins were separated on 12% SDS-PAGE gels or 4-12% gradi-
ent gels (NuPAGE 4-12% BisTris protein gels, Thermo Fisher). 
12% SDS-PAGE gels were cast with two layers, the resolving 
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layer (12% acrylamide solution, 0.385 M Tris-Cl pH 8.8, 0.1% 
SDS, 0.1% Ammonium persulfate (APS), 0.04% Tetramethyleth-
ylenediamine (TEMED)) and the stacking layer (5% acrylamide 
solution, 0.05 M Tris-Cl pH 6.8, 0,1% SDS, 0.1% APS, 0.1% 
TEMED). Samples were mixed with 4x NuPAGE LDS sample buff-
er and 10x sample reducing agent (both from Thermo Fisher). 
After heating at 70°C for 10 min samples were centrifuged at 
18,400 x g for 10 min at room temperature. 5 µl Magic Mark XP 
Western Protein Standard (Thermo Fisher) or Novex Sharp Pre-
Stained Protein Standard (Thermo Fisher) were used as marker. 
Electrophoresis was carried out with Tris-glycine buffer (25 mM 
Tris, 250 mM glycine, 0.1% SDS) or, if gradient gels were used, 
with NuPAGE MES or MOPS SDS running buffer (Thermo Fisher) 
with 110 V until the samples were stacked and 130 V until the 
gel running was stopped.  
Proteins were transferred onto Polyvinylidene difluoride (PVDF) 
membrane (PVDF Western Blotting Membranes (Roche) if the 
Stella 3200 imaging system (raytest) was used for detection, 
Immobilon-FL PVDF membrane (Merck Millipore) if Odyssey CLx 
imaging system (LiCor) was used) as follows: The SDS-PAGE gel 
was added onto the membrane activated with methanol and 
incubated in transfer buffer (25 mM Tris, 190 mM glycine, 20% 
methanol) or NuPAGE transfer buffer (Thermo Fisher). Gel and 
membrane were sandwiched between one layer of Whatman 
filter paper and sponge and inserted into a transfer tank for wet 
electroblotting (Bio Rad) filled with transfer buffer. Blotting was 
carried out with 35 mA over night at 4°C. The blot was washed 
two times for 10 min with Tris-buffered saline (TBS) with 0.1% 
Tween 20 (Sigma) (TBST), blocked for 1 h with blocking buffer 
(4% milk or 5% BSA in TBST or LiCor blocking buffer), washed 
once for 5 min with TBST and probed with the primary antibody 
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over night at 4°C. The blot probed with anti-Ubiquitin VU-1 
(LifeSensors) was treated differently according to manufactur-
er’s instructions. Unbound primary antibody was removed by 
washing four times for 5 min with TBST. The blot was re-probed 
with the appropriate secondary antibody conjugated to horse-
radish peroxidase (HRP) (anti-mouse IgG, 1:5000, #7076, Cell 
Signaling Technology) or with IRDye800CW goat anti-mouse 
(1:15000, LiCor) for 1 h at room temperature. After washing four 
times for 5 min with TBST the blot was developed with ECL 
(Amersham ECL Prime Western Blotting Detection Reagent, GE 
Healthcare) following manufacturer’s instructions and detected 
with Stella 3200 imaging system (raytest) or directly detected 
after re-probing with the secondary antibody with Odyssey CLx 
imaging system (LiCor).  
2.1.10.1 Total protein gel staining  
15 µL SDS-insoluble proteins dissolved in formic acid and dia-
lyzed against 50 mM Tris pH 7.5, 1 mM DTT, 0.1 mM PMSF (as 
described at 2.1.12.1) were loaded on a 12% SDS gel. Electro-
phoresis was carried out as described above. The gel was stained 
with Sypro Ruby protein gel stain following the manufacturer’s 
instructions (Thermo Fisher). 
2.1.10.2 Total protein blot staining 
For the analysis of post-translational modifications, 6 µl RIPA 
samples (soluble proteins) and 9 µl Urea/SDS samples (insoluble 
proteins) of C. elegans from 2.1.8 were loaded on a 12% SDS gel.  
For the total protein staining of SDS-insoluble proteins of 
wildtype mouse brains dissolved in formic acid and dialyzed 
against 50 mM Tris pH 7.5, 1 mM DTT, 0.1 mM PMSF (as de-
scribed at 2.1.12.1) one tenth of the original volume after dialysis 
were loaded on a 4-12% gradient gel.  
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Electrophoresis and electroblotting were carried out as de-
scribed above. The blots were stained with Sypro Ruby protein 
blot stain following the manufacturer’s instructions (Thermo 
Fisher). 
2.1.10.3 Western blot analysis of PAR-5 (14-3-3) 
9 µl Urea/SDS samples (insoluble proteins) from 2.1.8 were 
loaded on a 4-12% gradient gel. The membrane was probed with 
anti-14-3-3 (1:5000, SC-1657, Santa Cruz Biotechnology). The 
quantification was done with ImageJ.  
2.1.10.4 Western blot analysis of post-translational modifications  
6 µl RIPA samples (soluble proteins) and 9 µl Urea/SDS samples 
(insoluble proteins) from 2.1.8 were loaded on a 12% SDS gel. 
The membrane was probed with anti-Phosphotyrosine (1:500, 
Merck Millipore) or anti-Ubiquitin VU-1 following the manufac-
turer’s instructions (1:1000, VU101, LifeSensors). 
2.1.11 FRANK assay (Fibrillization of Recombinant Aβ Nucle-
ation Kinetic) 
The FRANK assay was performed by Anika Bühler and super-
vised by Dr. Frank Baumann at the Hertie Institute for Clinical 
Brain Research, Tübingen. The seeding potential of soluble or 
insoluble protein extracts from C. elegans and wild-type mouse 
brains was detected by measuring Thioflavin T (ThT) fibrilliza-
tion kinetics as described by (Nagarathinam et al. 2013) with the 
modifications as described in detail in (Marzesco et al. 2016; 
Nielsen et al. 2001). In brief: All kinetic measurements were 
carried out with 20 µM soluble recombinant Aβ(1-40) in 50 mM 
Phosphate buffer pH 7.4 and 150 mM NaCl with 20 µM ThT sup-
plemented with protease inhibitors (Complete Protease Inhibi-
tor Cocktail, Roche). Each assay was performed with freshly 
monomerized Aβ1-40. Briefly, lyophilized recombinant Aβ1-40 
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peptide was dissolved to a stock-concentration of 5 mM in 100% 
DMSO and frozen at - 80°C. Before use, this stock was then fresh-
ly diluted in DMSO to 400 µM and sonified for 20 min in a water 
bath followed by 30 min centrifugation at 22,000 x g at room 
temperature. The supernatant was then further diluted to reach 
200 µM Aβ1-40 in a 50% DMSO stock. In 96-well plates (µclear 
non-bind plate, Greiner), eight technical replicates were meas-
ured for each sample. The plates sealed with film sheets were 
incubated at 37°C for up to two to three days. The fluorescence 
measurements were performed from the bottom of the plate on 
a Fluostar Omega plate reader (BMG Labtech) (excitation: 
440 nm, emission: 480 nm) at 30 min interval after double or-
bital shaking for 30 s at 500 rpm. Increase of fluorescence over 
time was followed until the maximum was reached. For each 
sample, five to eight replicates were averaged and the lag times 
were determined from fitted curves (Nielsen et al. 2001) with 
GraphPad Prism 5. For this assay, the peptide Aβ(1-40) was ex-
pressed and purified as described earlier (Hortschansky et al. 
2005) by Prof. Marcus Fändrich at the University Ulm. Bicincho-
ninic acid (BCA) protein assay was performed to determine the 
total protein content in the soluble or detergent-insoluble pro-
tein fractions. For all experiments (with C. elegans and mice) 
0.001 µg was used. 
2.1.12 Mass spectrometry analysis 
SDS-insoluble proteins dissolved in formic acid were further 
processed for mass spectrometry analysis. Two biological repli-
cates of C. elegans (Table 2.4 replicate 1 and 2) with four differ-
ent time points each (day 2, day 6, day 10, day 14) were analyzed 
with mass spectrometry. SDS-insoluble protein extracts of three 
hemispheres of three young and three old wild-type mouse 
brains (six hemispheres in total) (Table 2.3) were analyzed.  
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2.1.12.1 Dialysis 
Insoluble proteins dissolved in formic acid were dialyzed against 
50 mM Tris pH 7.5, 1 mM DTT, 0.1 mM PMSF as follows: Three 
times 65 µL insoluble protein of one condition were added onto 
three membranes (Membrane filters 0.025 µM, Millipore) placed 
on the buffer surface in a 1-liter-beaker. For C. elegans, each con-
dition was divided onto six membranes. For mouse brains, each 
condition was divided onto three membranes. The pH of one 
sample was analyzed by removing 5 µL and adding it onto a pH 
strip. The sample was collected at a pH between 7 and 8 (approx-
imately after two hours). Finally, 10 µL dialysis buffer was used 
to wash the precipitate off each membrane.  
2.1.12.2 Preparation for mass spectrometry 
The amount of insoluble proteins in the dialyzed samples was 
evaluated by loading an aliquot onto a 4-12% gradient gel to-
gether with a reference sample of known concentration. A Sypro 
Ruby protein gel staining (Thermo Fisher) was performed ac-
cording to manufacturer’s instructions and the protein amount 
was quantified with ImageJ. This step was necessary to estimate 
the amount of trypsin needed for the digestion (described later). 
The samples were concentrated using a centrifugal evaporator 
(Concentrator plus, Eppendorf). The insoluble proteins were 
solubilized in a final concentration of 8 M urea. Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP, Serva) was added 
to a final concentration of 4 mM and incubated for 1 h at 57°C 
with 300 rpm. Iodoacetamide (Serva) was added to a final con-
centration of 8.4 mM and incubated for 45 min in the dark at 
room temperature. The samples were diluted in 150 mM ammo-
nium bicarbonate (Sigma Aldrich) to obtain a final 2 M urea con-
centration. Proteins were digested with 5% w/w modified tryp-
sin (Promega) overnight at 37°C and 400 rpm. A sample of the 
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digested proteins was loaded on a 12% SDS gel and Sypro Ruby 
protein gel or blot staining (Thermo Fisher) (as described at 
2.1.10.1 and 2.1.10.2) were performed to analyze if the digestion 
worked.  
2.1.12.3 Mass spectrometry and data analysis with C. elegans 
samples 
Peptides from C. elegans at day 2, day 6, day 10 and day 14 from 
two biological replicates were labelled by 8-plex isobaric tags for 
relative and absolute quantitation (iTRAQ) following the manu-
facturer's instructions (Applied Biosystems).  
Mass spectrometry and data analysis were performed by Dr. Ka 
Wan Li, Pim van Nierop and Prof. August B. Smit at the VU Uni-
versity Amsterdam as described (Klemmer et al. 2011). The 
iTRAQ-tagged samples were pooled, dried and peptides partially 
separated in a strong cation exchange column (2.1 x 150-mm 
PolySUFOETHYL A column, PolyLC Inc). Peptides in each collect-
ed fractions were further fractionated by capillary reverse phase 
C18 column (150 mm x 100 µm-inner diameter column packed 
in house with the Alltima C18 3 µm particle using the pressure 
injection cell from Next Advance). The eluents were continuously 
mixed with matrix (α-cyanohydroxycinnamic acid), and deposit-
ed off-line to the metal target every 15 s. The peptides were ana-
lyzed on the 5800-proteomics analyzer (AB-Sciex). Tandem mass 
spectrometry (MS/MS) spectra were each collected from 2500 
laser shots; a maximum of 25 MS/MS was allowed per spot. Mas-
cot was used to annotate spectra that were searched against C. 
elegans UniprotKB database. 
The peak areas of each iTRAQ signature ions were log2-
transformed and normalized to the total peak area of the signa-
ture peaks. The peak areas in each sample were mean-centered, 
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which were used to calculate the protein averages. The permuta-
tion-derived false discovery rate (q-value) was calculated by the 
excel plug-in of the Significant Analysis of Microarrays (SAM) 
program (Van Nierop 2011). 
2.1.12.4 Ingenuity Pathway Analysis 
Human homologs of early-aggregating proteins and late-
aggregating proteins in C. elegans (as described at 3.1.3) were 
identified using cildb 3.0 (http://cildb.cgm.cnrs-gif.fr) and En-
sembl genome browser 87 (http://www.ensembl.org/ 
index.html). 83 human homologs of early-aggregating proteins 
and 116 human homologs of late-aggregating proteins including 
early-aggregating proteins that continued to aggregate strongly 
at day 10 and day 14 were analyzed together with 161 minor 
components of AD pathological aggregates previously published 
(Ayyadevara, Balasubramaniam, Parcon, et al. 2016; Liao et al. 
2004; Wang et al. 2005) using Ingenuity Pathway Analysis (IPA 
Winter Release 2016, www.ingenuity.com). Fisher’s exact test 
was used to calculate a p-value reflecting the probability that the 
association between the set of molecules and a given pathway is 
due to chance alone. The threshold of the p-value for association 
was set to 0.01. This analysis was performed by our colleague Dr. 
Chaolie Huang. 
2.1.12.5 Mass spectrometry and data analysis with mice samples 
Labeling of the samples and nano-liquid chromatography-
MS/MS (nanoLC-MS/MS) analysis were performed by Dr. Ana 
Velic at the Proteome Center Tübingen. Peptides from three 
young and three old wild-type mouse brains were labelled with 
heavy and light dimethyl at lysine residues and N-termini as 
follows (published at (Spat, Macek, and Forchhammer 2015)): 
Samples were on-column (SepPak C18) dimethylation labeled as 
described previously (Boersema et al. 2009). In brief, 5 mL of the 
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respective labeling solutions with CH2O (Sigma-Aldrich) and 
NaBH3CN (Fluka) for light- and 13CD2O (Sigma-Aldrich) and 
NaBD3CN (Sigma-Aldrich) for heavy labeling were flushed with 
15 min contact time through the column. Labeled peptides were 
washed with 5 mL HPLC Solvent A (0.5% acetic acid) on the col-
umn and eluted with HPLC Solvent B (80% acetonitrile in 0.5% 
acetic acid). For validation of labeling efficiency and correct mix-
ing of the labeled peptides, two times 5 μg of each labeled sample 
(based on Bradford measurements) were used for separate 
measurements or mixed 1:1 and subjected after purification by 
C18 stage tips (Ishihama, Rappsilber, and Mann 2006) to pilot 
LC-MS/MS measurements. Based on the obtained label ratios, 
correction factors were applied for correct mixing of samples. 
For nanoLC-MS/MS analyses peptides were loaded onto an in-
house packed 15 cm reverse-phase C18 (3 μm; Dr. Maisch) na-
noHPLC column on an EasyLC nano-HPLC (Proxeon Biosystems). 
Separation was performed by 230 min segmented linear gradi-
ents with 5–90% HPLC solvent B. Eluted peptides were directly 
ionized and measured on a LTQ Orbitrap Elite mass spectrome-
ter. Mass spectrometers were operated in the positive ion mode. 
The LTQ Orbitrap Elite was conducting higher energy collision 
dissociation (HCD) of the 15 most intense multiply charged ions 
at the same scan range at resolution 120,000. Dynamic exclusion 
of sequenced precursor ions for 90 s and the lock mass option 
(Olsen et al. 2005) for real time recalibration were enabled on 
both instruments. 
All raw MS spectra were processed with MaxQuant software 
suite (version 1.5.3.12) (Cox et al. 2009) and default settings. 
Identified peaks were searched against the target-decoy mouse 
databases of Uniprot (http://www.uniprot.org) with the follow-
ing database search criteria: trypsin was defined as cleaving 
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enzyme and up to two missed cleavages were allowed. Carbami-
do-methylation of cysteines was set as a fixed, and methionine 
oxidation and protein N-termini acetylation were set as variable 
modifications. Light- and heavy-dimethylation labeling on pep-
tide N-termini and lysine residues was defined. The initial mass 
tolerance of precursor ions was limited to 6 ppm and 0.5 ppm for 
fragment ions. False discovery rates (FDRs) of peptides and pro-
teins were set to 1%, respectively. Quantification of dimethyla-
tion labeled peptides required at least two ratio counts. Peptides 
were only allowed with a posterior error probability (PEP) <1% 
at the peptide level.  
Perseus 1.5.1.6 was used for the statistical analysis of the 
MaxQuant output. Proteins only identified by site (proteins only 
identified with modified peptides), by reverse peptides and po-
tential contaminants were removed. Peptide ratios were log2-
transformed (as described in 3.1.8). Three replicates were ana-
lyzed together, resulting to 617 proteins that can be found in all 
replicates.  
2.1.12.6 Identification of C. elegans homologs of insoluble mouse 
brain proteins  
C. elegans homologs of proteins that aggregate the most in wild-
type mouse brains (as described at 3.1.8) were identified using 
cildb 3.0 (http://cildb.cgm.cnrs-gif.fr) and Ensembl genome 
browser 87 (http://www.ensembl.org/index.html). 
2.1.13 Motility analysis and paralysis assay with C. elegans 
overexpressing Aβ 
2.1.13.1 Preparation of Aβ overexpressing worms and speed 
measurement 
To measure the motility of Aβ overexpressing worms (GMC101) 
compared to N2 worms or to analyze if the motility is influenced 
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by a knockdown of a specific protein, worms were kept at 20°C 
until Aβ overexpressing worms started to paralyze (usually at 
day 5 or day 6) (worms were defined as paralyzed if they only 
moved their heads when touched with a platinum wire) and 
transferred on NG plates without bacteria. To transfer rapidly a 
large number of worms onto NG plates for motility measure-
ment, a previously described protocol (Ramot et al. 2008) was 
used with slight modifications. 40 worms were picked into M9 
buffer with 0.001% Triton X 100 (AppliChem) and shortly centri-
fuged. 20 µL containing concentrated worms were pipetted onto 
a stack of four Whatman paper disks (1.7 cm x 1.4 cm). The top 
disk was inverted onto a NG mini plate (diameter 3.5 cm) pre-
pared with a Whatman filter paper border with inside dimen-
sions of 2 cm x 1.7 cm, resulting to a transfer of around 30 
worms. Because worms try to avoid cupper, the border was 
soaked with 100 mM CuCl2. Worms were kept for 30 min at room 
temperature. The motility of Aβ overexpressing worms 
(GMC101) compared to N2 was measured by taking videos two 
times for 10 min and two times for 20 min (3 frames/s) with 
StreamPix 6 (Norpix) software and the camera BM 500 (JAI). 
After the first comparison the settings were changed. Videos 
were taken 10 times for 30 s with 30 s pauses in between 
(7.5 frames/s). For the video analysis, the Parallel Worm Tracker 
software was used with MathWorks MATLAB R2015b (as de-
scribed at (Ramot et al. 2008)). To be able to use the software 
published in 2008 some changes were made in the MATLAB code 
by Björn Müller (CIN, Tübingen) and Angelos Skodras (DZNE, 
Tübingen). The settings were obtained from Dr. Jan Kubanek 
(Stanford University, USA) and are shown in 6.2. The first set-
tings were needed to track a video with the new MATLAB ver-
sion. The second settings were necessary to be able to analyze 
videos taken for other time periods than 30 s. Each analysis was 
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controlled manually. If only a few worms were detected and 
measured by the software the respective video was removed. 
Because the motility measurements with the Parallel Worm 
Tracker software were not reproducible, a motility analysis 
plugin (called “wrMTrck”) for ImageJ described by Jesper S. 
Pedersen (http://www.phage.dk/plugins/download/wrMTrck. 
pdf) was used with the following settings: Minimum size 
50 pixels, maximum size 400 pixels, maximum velocity 
50 pixels/frame, maximum area change 100%, minimum track 
length 10 frames, frames per second 7.5 and set scale 
30 pixel/mm.  
2.1.13.2 Knockdown of proteins with RNA interference (RNAi) for 
motility analysis 
One to two days in advance, NG plates with 50 µg/mL Carbenicil-
lin (Carb) and 1 mM IPTG (NG/Carb/IPTG) were prepared with 
control bacteria or RNAi bacteria (Table 2.6) to inhibit the gene 
of interest (detailed protocol about RNAi in C. elegans: JoVE Sci-
ence Education Database. Essentials of Biology 1: 
yeast, Drosophila and C. elegans. RNAi in C. elegans. JoVE, Cam-
bridge, MA, doi: 10.3791/5105 (2017)). Two bacterial libraries 
(established by Julie Ahringer and Marc Vidal) were used with 
bacteria expressing the double stranded RNA needed for the 
RNAi. Once the offspring reached the L4 larval stage, L4s were 
transferred onto NG/Carb/IPTG plates seeded with control RNAi 
or RNAi bacteria for the gene of interest and kept at 20°C. The 
aging worms were transferred away from their progeny to new 
plates every second day until the end of their reproductive peri-
od in order to be able to distinguish them from their offspring. 
After knockdown of early-aggregating proteins that continued to 
aggregate strongly at day 10 and day 14 (NEX-1 and LEC-5, Table 
2.6), the average speed of worms was measured between day 3 
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and day 6 as described above. Most of this part was performed 
by the intern Stavros Vagionitis.  
After transferring Aβ overexpressing worms on different control 
RNAi’s (Table 2.6) for the knockdown of C. elegans homologs of 
insoluble proteins that aggregate the most in wild-type mouse 
brains, the motility was measured at day 6 as described above 
with the following changes: For each condition (three different 
control RNAi’s) three plates with 20 worms were prepared. Vid-
eos were taken five times for 30 s with 30 s pauses, resulting to 
five videos per plate and 15 videos per condition. For compari-
son, videos were analyzed with the Parallel Worm Tracker soft-
ware and ImageJ.  
  Table 2.6: RNAi bacteria used for motility analysis of Aβ overexpressing 
worms (GMC101). 
RNAi bacteria 
(gene name) 
Source (JA: Julie  
Ahringer, MV: Marc 
Vidal RNAi library) 
Description 
L4440 JA 
Control RNAi,  
empty vector 
GFP 
Cynthia Kenyon’s lab 
at UCSF 
Control RNAi 
her-1 JA Control RNAi 
nex-1 (ZC155.1) MV  
lec-5 (ZK1248.16) JA  
 
2.1.13.3 Paralysis Assay  
To compare the paralysis levels of worms overexpressing PAR-5 
(UE50), Aβ (GMC101) or both (double transgenic, DCD296), 105 
L4s of each overexpressing strain were kept at 20°C. At day 1 of 
adulthood, worms were transferred to 25°C to induce paralysis 
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(McColl et al. 2012). The numbers of paralyzed worms were 
counted from day 2 to day 4 (until most of the double-transgenic 
worms were paralyzed). Worms were defined as paralyzed if 
they only moved their heads when touched with a platinum wire. 
2.1.13.4 Staining of Aβ-overexpressing worms with K114 and con-
focal analysis 
For the staining of Aβ amyloids in Aβ-overexpressing GMC101 
worms with the Congo red analogue (trans, trans)-1-bromo-2,5-
bis-(4-hydroxy)styrylbenzene (K114), age-synchronized worms 
were shifted to 25°C at day 1 and collected when they started to 
paralyze (day 2). The fixation protocol for confocal analysis was 
adapted from a fixation protocol previously described (Antibody 
Staining of C. elegans by Michael Koelle, 
https://medicine.yale.edu/lab/koelle/protocols/Antibody%20S
taining_180540_21947.pdf). Worms were picked into 300 µL M9 
buffer, shortly centrifuged and the supernatant was removed. 
Worms were washed once with 500 µL ddH2O (ddH2O was add-
ed, the tube was rotated, worms were shortly centrifuged and 
the supernatant was removed) before being resuspended in 
fixation solution containing 1% PFA (Sigma). After mixing thor-
oughly, worms were immediately immersed into liquid nitrogen 
for freezing. Worms were thawed at 70°C and refrozen in dry ice 
two times and then rotated for 3 h at 4°C. Worms were washed 
three times as described above with 500 µL PBST-B buffer (1x 
Phosphate-buffered saline (PBS) pH 7.4, 0.1% Bovine serum 
albumin (BSA) (Sigma), 0.5% Triton X 100 (AplliChem), 5 mM 
sodium azide, 1 mM EDTA). Worms were stained with 50 µL 
1 mM K114 (VWR) in PBST-A buffer (same as PBST-B buffer 
except 1% BSA) for 90 min in the dark at room temperature, 
washed four times with PBST-B and placed on a slide using Fluo-
rescent Mounting Medium (Dako). Worms were examined under 
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a Leica SP8 confocal microscope with the HC PL APO CS2 
63x1.40 oil objective using the Leica HyD hybrid detector. K114 
was detected using 405 nm as excitation and an emission range 
from 450 to 486 nm. 
2.1.14 Intracerebral injection of insoluble proteins into 
young, pre-depositing APP23 transgenic mice 
The intracerebral injection and analysis were performed by Ul-
rike Obermüller and supervised by Dr. Frank Baumann at the 
Hertie Institute for Clinical Brain Research, Tübingen. 
All APP23 transgenic mice used were bred and maintained under 
pathogen-free conditions at the Hertie Institute for Clinical Brain 
Research, Tübingen. All studies were performed in accordance 
with German animal welfare legislation and with approval from 
the Ethical Commission for animal experimentation of Tübingen, 
Germany (“Tierversuchsantrag N03/11”). 
For the injection of insoluble protein extracts into the hippo-
campi of APP23 transgenic mice a mix of insoluble protein ex-
tracts of aged (total volume of 60 µL) or young (total volume of 
40 µL) wild-type mouse brains, that were obtained as described 
for the FRANK assay at 2.1.9, was prepared (Table 2.7). Per hem-
isphere 2.5 µL of the mix were injected bilaterally stereotacticly 
into the hippocampi of five recipient mice (injection of extract 
mix of aged mice) or four recipient mice (injection of extract mix 
of young mice) (Table 2.8). All recipients were three months of 
age when injected and were killed, perfused and histologically 
analyzed six months after injection. 
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Table 2.7: Mice used as donors for intracerebral injection. Shown are the 
sex of the mice, age and volume for the mix of insoluble protein extracts. 
Mouse Sex Age (months) 
Volume used 
for injection 
524 female 18 3x 10 µl  
503 female 19 1x 10 µl 
7830  male 18 1x 10 µl  
7831 male 18 1x 10 µl 
8418 female 2 1x 10 µl  
8419 female 2 1x 10 µl 
 8628   male 3 1x 10 µl 
8629 male 3 1x 10 µl 
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Table 2.8: Mice used as recipients for intracerebral injections. Shown are 
the sex of the mice, age when histologically analyzed and injected protein 
extract (from aged or young mice).  
Mouse Sex Age (months) Extract 
451 female 10 aged 
512 female 10 aged 
518 female 10 aged 
525 female 10 aged 
526 female 10 aged 
832 male 10 young 
853 male 10 young 
864 female 9 young 
865 female 9 young 
 
2.1.15 Statistics 
For the FRANK Assays significance was tested with unpaired t-
test (p<0.05), One-way ANOVA (p<0.05) or Two-way ANOVA 
(p<0.05) using Graph Pad Prism 7. For Figure 3.1C the relative 
seeding activity was calculated using the normalization function 
of Graph Pad Prism 7. The absolute lag times measured for four 
biological replicates were normalized to those of the standards. 
The lag time of a soluble extract from day 2 worms (negative 
control) was defined as 0% and the lag time of an insoluble ex-
tract from transgenic C. elegans overexpressing Aβ (GMC101, 
positive control) was defined as 100%. 
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For the motility analysis of Aβ-overexpressing worms subjected 
to RNAi bacteria an unpaired t-test (p<0.05) or One-way ANOVA 
(p<0.05) was performed using Graph Pad Prism 7.  
For the comparison of the paralysis levels of PAR-5 overexpress-
ing worms, Aβ overexpressing worms and the double-transgenic 
worms overexpressing both proteins, Fisher’s exact test was 
used (http://www.socscistatistics.com/tests/fisher/default2. 
aspx).  
The Spearman r for the correlation between different replicates 
of quantitative mass spectrometry with insoluble proteins from 
young and old wild-type mouse brains was calculated with the 
correlation analysis of Graph Pad Prism 7. 
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2.2 Investigation whether rapidly-aggregating proteins 
seed the aggregation of other proteins 
2.2.1 C. elegans mutant and transgenics 
Table 2.9: C. elegans mutant and transgenic strains used in this study. 
Strain name Genotype 
CF2137 fem-1(hc17ts)IV 
DCD187 
uqIs19[Pmyo-2::rho-1::hisavi + Pmyo-2:: 
birAtagRFP] 
DCD243 
(CF2137;DCD187) 
fem-1(hc17ts)IV; uqIs19[Pmyo-2::rho-1::hisavi + 
Pmyo-2::birAtagRFP] 
 
2.2.2 Bacterial Strains 
See 2.1.2.  
2.2.3 Growing and Maintenance of C. elegans  
As described at 2.1.4.  
2.2.4 Cloning and strain generation 
In order to isolate rapidly-aggregating proteins and their co-
aggregating proteins, a tandem-affinity purification strategy in 
denaturing conditions was used. For this, an aggregation-prone 
candidate was tagged with a tandem-affinity tag combining a 
biotin signal with a hexa-histidine sequence (called histidine-
avidin tag) (Schaffer et al. 2010; Tagwerker et al. 2006). The 
avidin tag is known as AviTag, an artificial target motif for bioti-
nylation by the E. coli biotin holoenzyme synthetase birA 
(Schaffer et al. 2010). 
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For the method development to crosslink, isolate and identify 
rapidly-aggregating proteins together with their co-aggregating 
proteins, a transgenic strain was generated overexpressing RHO-
1 (a Rho GTPase orthologous to transforming protein RhoA in 
mammals) with a histidine-avidin tag at the C-terminus together 
with the biotinylation enzyme birA fused to tagRFP. Cloning was 
carried out using the Gateway system (Invitrogen, Carlsbad, CA, 
USA). The promoter Pmyo2 was obtained from Brian Lee (UCSF, 
USA) and the cDNA of the rho-1 gene was obtained from Open 
Biosystems (Thermo Scientific, Huntsville, AL, USA). The Gate-
way vector with histidine-avidin tag was generated by Dr. Emily 
Crawford. The biotinylation enzyme birA was obtained from Dr. 
Ekkehard Schulze (University Freiburg) with the construct 
Pmyo3::birA::mCherry. The tagRFP gene was obtained from 
Evrogen (AXXORA, San Diego, CA, USA). Constructs were se-
quenced at each step.  
The transgenic C. elegans line expressing RHO-1 tagged with 
histidine-avidin and birA fused to tagRFP under the control of 
the pharyngeal muscle-specific promoter Pmyo-2 was generated 
as follows: The construct containing Pmyo2::rho-1::hisavi was 
injected at 30 ng/µL together with the plasmid containing 
Pmyo2::birAtagRFP at 100 ng/µL into N2 animals by Katja Wid-
maier (as described at (Evans 2006), http://www.wormbook. 
org).  
The extrachromosomal array was integrated by UV irradiation 
with the CL-1000 Ultraviolet Crosslinker (UVP) with 
275,000 µJ/cm2 as follows: 100 young adults of the strain were 
irradiated, separated to 10 worms per plate and incubated at 
20°C. Irradiated adults were transferred to new plates every day 
until day 3. The progeny was also kept at 20°C. After starvation 
100 L1s from each day were picked onto 100 plates and kept at 
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20°C to produce progeny. Worms were checked for 100% inher-
itance (100% fluorescence) with a fluorescence microscope. 
Worms were backcrossed four times with N2 males to remove 
potential mutations caused by UV irradiation during integration 
of a transgene, resulting to the strain DCD187, as follows: 12 N2 
males and three L4 hermaphrodites of the transgenic strain were 
mated. From the mating plate three L4s were picked for the next 
backcross with 12 N2 males. The last step was repeated until the 
transgenic strain was backcrossed four times with N2 males. 
Nine L4s were picked from the mating plate onto separate plates 
to produce progeny. From the progeny 20 L1s were added onto 
separate plates. The progeny was analyzed for 100% transmis-
sion of the transgene. 
The C. elegans transgenic strain overexpressing RHO-1 tagged 
with histidine-avidin and overexpressing the biotinylation en-
zyme birA fused to tagRFP (DCD187) with temperature-induced 
sterility was generated as follows: N2 males were crossed with 
temperature induced sterile fem-1 mutant hermaphrodites 
(CF2137) as described at 2.1.4. CF2137 males were mated into 
DCD187 hermaphrodites as described at (Fay 2013), resulting to 
the strain DCD243. 
2.2.5 C. elegans liquid culture 
The C. elegans transgenic strain overexpressing RHO-1 tagged 
with histidine-avidin, overexpressing the biotinylation enzyme 
birA and bearing the fem-1 mutation (DCD243) to get tempera-
ture induced sterile worms was used to obtain a large aged-
synchronized population. The same protocol was used as de-
scribed at 2.1.6 with the following changes: To collect the paren-
tal generation for the temperature shift, worms were first grown 
on 10 NG plates seeded with OP50 at 20°C until plates were con-
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fluent, washed from the plates with M9 and grown in liquid cul-
ture with OP50-1 at 20°C instead of growing the worms on HGM 
plates.  
When most animals were adults and L1s were hatching, eggs and 
L1s were separated from the adults by sedimentation as de-
scribed at 2.1.6.2. After L1 arrest overnight at 25°C, L1s were 
counted and 300,000 L1s were grown with OP50-1 at 25°C. At 
day 1, worms were collected and removed from bacteria and 
dead worms by sucrose separation as described at 2.1.6.5. The 
resulting worm pellet was frozen in liquid nitrogen with an equal 
volume of RAB high-salt buffer with inhibitors. The frozen worm 
pellet was ground in a mortar as described at 2.1.6.6.   
For the method development of chemical crosslinking and purifi-
cation non-sterile C. elegans transgenic worms overexpressing 
RHO-1 with histidine-avidin tag and the biotinylation enzyme 
birA (DCD187) were collected at day 1 as described above and 
ground in a mortar.  
2.2.6 Insoluble protein extraction with chemical crosslink-
ing 
2.2.6.1 Method development without chemical crosslinking 
To establish the purification protocol protein extractions with-
out crosslinking were performed with non-sterile C. elegans 
transgenic worms overexpressing RHO-1 with histidine-avidin 
tag and the biotinylation enzyme birA (DCD187) collected at day 
1.  
After grinding of the frozen worm pellet as described at 2.1.6.6, 
the protocol for insoluble protein extraction for mass spectrome-
try with C. elegans described at 2.1.7 was followed until resus-
pension and centrifugation with the RIPA buffer. After centrifu-
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gation the supernatants were removed and the two pellets re-
sulting from two times 350 mg powder were resuspended with 
300 µL urea buffer each. For the first extraction urea buffer A 
(8 M urea, 20 mM sodium phosphate pH 7.4, 500 mM NaCl, 
10 mM imidazole) was used. For the second extraction for the 
purification with harsh conditions urea buffer 1 (8 M urea, 
300 mM NaCl, 0.5% NP40, 50 mM sodium phosphate, 50 mM 
Tris pH 8) (Tagwerker et al. 2006) was used. After centrifugation 
at 18,400 x g for 20 min at 4°C the supernatants of one extraction 
containing highly insoluble proteins were combined, resulting to 
600 µL total volume. 
2.2.6.2 Chemical crosslinking with 0.4% Para-Formaldehyde 
(PFA) 
For the first chemical crosslinking with Para-Formaldehyde 
(PFA, Sigma) the protein extraction was performed as described 
above but the resuspension and centrifugation were done with a 
RIPA buffer free of primary amines containing 50 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 8 
instead of Tris. After centrifugation the supernatants were re-
moved and the two samples were pooled together after solubiliz-
ing each pellet with 500 µL RIPA buffer (with HEPES). After the 
suspension was drawn up into a syringe 10 times and centri-
fuged, all supernatant was removed and discarded. The pellet 
was resuspended with 700 µL 0.4% PFA in PBS pH 7.4. The sus-
pension was incubated for 10 min at room temperature on a 
nutating mixer. The reaction was quenched with 700 µL ice-cold 
2.5 M glycine in PBS (for a final concentration of 1.25 M glycine). 
After centrifugation at 18,400 x g for 20 min at 4°C the superna-
tant was removed. The final pellet was resolved with 600 µL 
urea buffer 1 and centrifuged at room temperature. The super-
natant containing crosslinked SDS-insoluble proteins was trans-
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ferred to a new tube. The pellet was resolved with 100 µL 2x SDS 
gel-loading buffer (100 mM Tris pH 6.8, 4% SDS, 0.2% bromo-
phenol blue, 20% glycerol, 200 mM DTT) and heated at 95°C for 
5 min for SDS gel or western blot analysis.   
2.2.6.3 Chemical crosslinking with Disuccinimidyl glutarate (DSG) 
Because the chemical crosslinking with PFA was to strong, a 
crosslinking with Disuccinimidyl glutarate (DSG, Thermo Scien-
tific) was performed as described for PFA with the following 
changes: After resuspension and centrifugation with RIPA buffer 
(with HEPES) for the second time, the pellet was resuspended 
with 700 µL 0.25 mM DSG, 0.025 mM DSG or 0.0025 mM DSG in 
PBS pH 7.4. The crosslinker was incubated for 30 min at room 
temperature on a nutating mixer. The reaction was quenched 
with 700 µL 100 mM Tris pH 7.5 (for a final concentration of 
50 mM Tris) for 15 min and centrifuged as described for PFA. 
The final pellet was resolved with 600 µL urea buffer 1 and cen-
trifuged at room temperature.  
2.2.7 Protein purification with Nickel affinity chromatog-
raphy  
All purifications were performed with the ÄKTA Pure 25 System 
and UNICORN control software (GE Healthcare) with a flow rate 
of 1 mL/min.   
2.2.7.1 Purification with imidazole 
For the first purification, the volume of the sample containing 
highly insoluble proteins of worms overexpressing RHO-1 with 
histidine-avidine tag (DCD187) was increased with urea buffer A 
to 800 µL. Before loading the sample onto a His-TrapTM FF col-
umn (column volume 1 mL, GE Healthcare), the sample was cen-
trifuged at 18,400 g for 20 min at 4°C to remove any particles. 
The column was equilibrated and the sample was loaded onto 
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the column with 20 column volumes (CV) urea buffer A, respec-
tively. The column was washed with 30 CV urea buffer A. The 
elution was performed with a linear gradient from urea buffer A 
to urea buffer B (8 M urea, 20 mM sodium phosphate pH 7.4, 
500 mM NaCl, 500 mM imidazole) over 20 CV. During all steps 
1 mL-fractions ("flow through" and "elution") or 3 mL-fractions 
("wash") were collected.   
2.2.7.2 Purification with harsh conditions 
 The purification under harsh conditions was performed as de-
scribed at 2.2.7.1, with the following changes: The column was 
equilibrated and the sample was loaded onto the column with 
20 column volumes (CV) urea buffer 1, respectively. The column 
was washed with 10 CV urea buffer 1, 10 CV urea buffer 1 pH 6.3 
and 10 CV urea buffer 1 pH 6.3 and 10 mM imidazole. The elution 
was performed with a linear gradient from urea buffer 1 pH 6.3 
and 10 mM imidazole to urea buffer 2 (8 M urea, 200 mM NaCl, 
50 mM sodium phosphate, 2% SDS, 10 mM EDTA, 100 mM Tris 
pH 4.3) over 20 CV. During all steps 1 mL-fractions ("flow 
through" and "elution") or 5 mL-fractions ("wash") were collect-
ed.   
2.2.8 Gel electrophoresis and Western blotting 
Gel electrophoresis and Western blotting were performed as 
described at 2.1.10. Before the samples (load, flow through, wash 
and elution fractions) were loaded onto a 4-12% gradient gel 
they were mixed with NuPage sample buffer as described and 
heated at 65°C for 10 min.  
2.2.8.1 Western blot analysis of histidine-avidin tagged proteins 
10 µL samples collected during purification were loaded on a 4-
12% gradient gel. The membrane was probed with horseradish 
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peroxidase (HRP)-conjugated Streptavidin (1:10,000, OC181939, 
Thermo Scientific).  
2.2.8.2 Silver staining  
The same volumes of samples were loaded as described at 
2.2.8.1. Silver staining was performed with the Pierce™ Silver 
Stain Kit (Thermo Scientific) according to the manufacturer’s 
instructions. 
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3 Results 
3.1 Identifying age-dependent heterologous seeds for 
amyloid-β aggregation 
Results and figures are mainly reproduced from: 
Groh N, Bühler A, Huang C, Li KW, van Nierop P, Smit AB, 
Fändrich M, Baumann F and David DC (2017) Age-Dependent 
Protein Aggregation Initiates Amyloid-β Aggregation. Front. 
Aging Neurosci. 9:138. Doi: 10.3389/fnagi.2017.00138 
3.1.1 Protein aggregates formed during normal C. elegans 
aging seed Aβ aggregation in vitro 
To investigate whether age-dependent protein aggregates 
formed during aging in C. elegans have the potential to seed the 
aggregation of synthetic Aβ in vitro, highly detergent-insoluble 
proteins from young and aged C. elegans were isolated as de-
scribed at 2.1.7. C. elegans has been extensively characterized as 
a model for aging (Antebi 2007) and widespread protein aggre-
gation with age has been repeatedly documented (David et al. 
2010; Reis-Rodrigues et al. 2012; Walther et al. 2015). As exten-
sive protein aggregation occurs in the reproductive tissues 
(David et al. 2010), a gonad-less C. elegans strain was used to 
investigate only somatic age-dependent protein aggregation. To 
identify seeding, changes in the lag time preceding the formation 
of Aβ(1-40) fibrils in vitro were examined using the FRANK assay 
(Fibrillisation of Recombinant Aβ Nucleation Kinetic) (Figure 
1.3B). This assay has been successfully used to quantify the seed-
ing activity of different cellular extracts containing Aβ seeds 
(Fritschi et al. 2014; Marzesco et al. 2016; Nagarathinam et al. 
2013). 
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Insoluble protein extracts from aged C. elegans (day 14, ~50% 
dead) significantly shortened the lag time of Aβ aggregation 
compared to extracts from young animals (day 2, 0% dead) 
(Figure 3.1A, p=0.039). Similar to a classical western blot, it is 
only meaningful to compare absolute lag time values evaluated 
in the same assay plate. However, despite variations between 
experiments, the difference in seeding activity between insoluble 
extracts from young and aged animals was highly reproducible 
(Figure 3.1). Consistent with the nature of a seed, only 0.001 µg 
of insoluble proteins from aged animals were needed to seed Aβ 
aggregation. To distinguish whether seeding is a general charac-
teristic of the aged proteome or specific to aggregated proteins, 
high-salt soluble proteins were evaluated with the in vitro assay. 
The lag time for Aβ aggregation remained similar for soluble 
proteins from aged and young animals and comparable to that 
observed with insoluble extracts from young animals (Figure 
3.1A). Together, these results demonstrate that protein aggre-
gates appearing during normal aging can serve as heterologous 
seeds for Aβ aggregation. 
3.1.2 Seeding activity appears in the later stages of life 
Sporadic AD is a late-onset disease affecting humans over age 65.  
However, it remains unclear when pathogenesis starts in the 
patients’ brains. To determine when the seeds triggering Aβ 
aggregation appear, insoluble extracts from different stages of 
adulthood were analyzed. For this, four time points were chosen: 
young animals (day 2), early middle-aged animals (day 6, at the 
end of reproduction in wild-type animals), late middle-aged an-
imals (day 10, ~30% of the population has died) and old animals 
(day 14, ~50% of the population has died). To collect large num-
bers of individuals for all time points, C. elegans were cultured in 
liquid. The whole procedure was performed four times to obtain 
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four different biological replicates. In order to compare the seed-
ing activities of all insoluble extracts measured in two separate 
assay plates, two standard extracts were included: a soluble 
extract as negative control and an insoluble extract from trans-
genic C. elegans overexpressing Aβ as positive control. The rela-
tive seeding activity was calculated by normalizing the absolute 
lag times measured for each biological replicate to those of the 
standards with 0% being the lag time of the negative control and 
100% being the lag time of the positive control. Sypro Ruby 
staining of insoluble proteins on an SDS gel showed accelerated 
protein aggregation with increasing age, especially between day 
10 and day 14 (Figure 3.1B). Evaluation of the relative seeding 
activity did not reveal a significant increase in seeding between 
day 2 and day 6 (Figure 3.1C, p= 0.57). Instead, a large increase 
in seeding activity at day 10 was found (p= 0.0086 compared to 
day 2). The seeding potential was not further increased in insol-
uble extracts from 14-day-old animals. When extrapolated to 
human aging, the appearance of heterologous protein aggregate 
seeds for Aβ aggregation at the later stages of life rather than 
early middle age would be consistent with the late-onset of AD 
dementia. 
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Figure 3.1: Insoluble protein extracts from aged C. elegans seed Aβ aggre-
gation in vitro (reproduced from Frontiers article).  
A: Lag times measured for Aβ aggregation in the presence of 0.001 μg C. 
elegans soluble and detergent-insoluble protein extracts (day 2 and day 
14). Mean values (blue lines soluble, red lines insoluble) with respective 
SEM of 3 biological replicates are represented (each including a minimum 
of five technical replicates). Two-tailed p-value: day 2 insoluble vs. day 14 
insoluble *p= 0.039. 
B: SDS gel of insoluble protein extracts from different ages stained with 
Sypro Ruby protein gel stain. 
C: Relative seeding activity measured for Aβ aggregation in the presence 
of 0.001 μg insoluble protein extracts from different ages. Mean values of 
four biological replicates (each including five technical replicates) are 
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shown. Data were normalized with 0% being the lag time of the negative 
control (soluble extract, day 2) and 100% being the lag time of the posi-
tive control (insoluble extract from C. elegans transgenics expressing Aβ). 
One-way ANOVA: day 2 vs. day 10 **p= 0.0086 and day 2 vs. day 14 
**p= 0.0051.  
3.1.3 Identification of early- and late-aggregating proteins 
during aging 
The results from the in vitro assay imply that changes in aggrega-
tion between day 6 and day 10 are responsible for seeding. 
Quantitative mass spectrometry was performed using the stable-
isotope iTRAQ reagents to identify these changes with two inde-
pendent biological repeats. 845 quantifiable aggregation-prone 
proteins were found. Of these, 460 were identified in a previous 
study (David et al. 2010). This large overlap attests to the quality 
of the present mass spectrometry analysis. After normalization, 
the proteins were ranked depending on their relative change in 
aggregation levels focusing on proteins with the highest change 
in aggregation with age, i.e. in the top 25th percentile in both 
repeats. Early-aggregating proteins were defined as present in 
the top 25th percentile of day 6 compared to day 2 and late-
aggregating proteins as present in the top 25th percentile of day 
10 or day 14 compared to day 6 (Figure 3.2). 133 proteins were 
detected at day 6 in the top aggregating fractions in both repli-
cates. Significantly among these early-aggregating proteins, the 
rate of aggregation continued to increase strongly for 23 pro-
teins at day 10 (in the top 25th percentile) as well as 30 proteins 
at day 14 (Figure 3.2; as opposed to 3.3 by chance, Table 3.1). 
Consequently, these latter proteins could also be responsible for 
seeding Aβ. At day 10 and day 14, 65 and 107 late-aggregating 
proteins were detected, respectively. Of these, 42 proteins (as 
opposed to 3.3 by chance, Table 3.1) were prone to aggregate 
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strongly at both later ages compared to day 6. As seeding activity 
appears in day 10 animals, these late-aggregating proteins are 
prime candidates.  
To identify functional groups associated with the early- and late-
aggregating proteins, an Ingenuity Pathway Analysis (IPA) was 
performed with the human homologs. Then, pathways that were 
also significantly associated with the minor components in AD 
pathological aggregates were investigated. This analysis high-
lighted eight pathways that tend to harbor both late-aggregating 
proteins and disease-related aggregate components, namely: 
proteins related to 14-3-3 mediated signaling, PI3K/AKT signal-
ing, ERK/MAPK signaling, Calcium Transport I as well as pro-
teins related to the ubiquitination pathway, aryl hydrocarbon 
receptor signaling, NRF2-mediated oxidative stress response and 
xenobiotic metabolism signaling (Table 3.2). The latter four cat-
egories were also significantly associated with early-aggregating 
proteins. These results predict that interactions between Aβ or 
tau with these pathway components could potentially induce or 
accelerate their aggregation. 
In addition to the pathway analysis, late-aggregating proteins 
that were also minor components in AD were identified. At day 
10 and/or day 14 the homologs of the following ten proteins 
were identified in amyloid plaques and/or NFTs: PAR-5, UBA-1, 
SPC-1, LMN-1, NEX-3, HIS-1, NKB-3, FRM-1, MCA-3 and GPD-1 
(Table 3.3). Importantly, seeding activity of the late-aggregating 
protein, 14-3-3 (human homolog of PAR-5), has already been 
demonstrated both in vitro and in cell culture, whereby 14-3-3 
initiates tau fibril formation (Hernandez, Cuadros, and Avila 
2004; Li and Paudel 2016; Qureshi et al. 2013). Western blot 
analysis confirmed that PAR-5 was highly prone to aggregate at 
day 10 compared to day 6 (3.2 fold, Figure 3.3). Conversely, six 
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minor components of amyloid plaques and/or NFTs were among 
the early-aggregating proteins in C. elegans. Of note, only one of 
these early-aggregating minor components, GST-1, continued to 
aggregate strongly at day 10 and day 14 and therefore could also 
play a role in Aβ seeding.  
To summarize, this quantitative proteomic analysis of the 
C. elegans aggregating proteome at different ages brings insight 
into which minor components of pathological protein aggregates 
could directly seed disease-associated aggregation. 
 
Figure 3.2: Schematic summarizing numbers of early- and late-
aggregating C. elegans proteins detected by quantitative mass spectrome-
try (reproduced from Frontiers article). Proteins with the highest aggre-
gation propensity at day 10 or day 14 are defined as proteins quantified in 
the top 25th percentile compared to day 6. Proteins with the highest ag-
gregation propensity at day 6 are defined as proteins quantified in the top 
25th percentile compared to day 2. Quantification was performed with two 
biological replicates and all numbers represent only proteins in the top 
25th percentiles from both replicates. *Proteins also among the 137 pro-
teins with the highest aggregation propensity at day 14 (in top right box). 
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Table 3.1: Comparison of actual and expected numbers of proteins in the 
top 25th percentile of two biological replicates (reproduced from Frontiers 
article). 
Proteins ranked in  
(two replicates) 
actual expected# 
Chi-
Square 
Test* 
Top 25th percentile of day 6 133 52.8 
4.38E-30 
Not in top 25th percentile of day 6 712 792.2 
Top 25th percentile of day 10 88 52.8 
5.71E-07 
Not in top 25th percentile of day 10 757 792.2 
Top 25th percentile of day 14 137 52.8 
5.45E-33 
Not in top 25th percentile of day 14 708 792.2 
Top 25th percentile of day 6 and 
day 10 
23 3.3 
1.71E-27 
Not in top 25th percentile of day 6 
and day 10 
822 841.7 
Top 25th percentile of day 6 and 
day 14 
30 3.3 
4.49E-49 
Not in top 25th percentile of day 6 
and day 14 
815 841.7 
Top 25th percentile of day 10 and 
day 14 
42 3.3 
4.59E-101 
Not in top 25th percentile of day 10 
and day 14 
803 841.7 
 
#Calculation: the expected probability of proteins to be ranked in the top 
25th percentile of two replicates is 1/16. In addition the expected 
probability of these proteins to be ranked in the top 25th percentile of two 
different days is 1/256. 
* Chi-Square Test has been performed with Excel formula CHITEST. 
 
 
 
Results 
 
61 
 
Table 3.2: Ingenuity Canonical Pathways identified in the set of late- or 
early-aggregating proteins and their association with minor components 
found in AD pathological aggregates (highlighted in grey)  (–log(p-value) 
> 2) (reproduced from Frontiers article). 
 -log(p-value) 
Ingenuity Canonical  
Pathways 
Late-
aggregating 
proteins 
Minor  
components 
Protein Ubiquitination  
Pathway 
6.82 2.57 
Aryl Hydrocarbon Receptor 
Signaling 
4.93 3.19 
Glutathione-mediated Detoxifi-
cation 
4.75  
EIF2 Signaling 4.54  
tRNA Charging 4.23  
mTOR Signaling 3.96  
LPS/IL-1 Mediated Inhibition of 
RXR Function 
3.67  
Regulation of eIF4 and p70S6K 
Signaling 
3.66  
PI3K/AKT Signaling 3.23 5.37 
ERK/MAPK Signaling 3.11 3.18 
Citrulline Biosynthesis 3.09  
Calcium Transport I 2.89 7.47 
Death Receptor Signaling 2.79  
Superpathway of Citrulline 
Metabolism 
2.59  
NRF2-mediated Oxidative Stress 
Response 
2.38 4.96 
Xenobiotic Metabolism  
Signaling 
2.31 2.92 
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14-3-3-mediated Signaling 2.25 13.4 
Endoplasmic Reticulum Stress 
Pathway 
2.24  
Glutathione Redox Reactions I 2.20  
Lipid Antigen Presentation by 
CD1 
2.06  
Ingenuity Canonical  
Pathways 
Early-
aggregating 
proteins 
Minor  
components 
EIF2 Signaling 5.68  
Protein Ubiquitination 
Pathway 
5.22 2.57 
Cell Cycle Control of Chromoso-
mal Replication 
4.87  
Aryl Hydrocarbon Receptor 
Signaling 
4.78 3.19 
NRF2-mediated Oxidative Stress 
Response 
4.01 4.96 
Creatine-phosphate Biosynthe-
sis 
3.84  
Glutathione-mediated Detoxifi-
cation 
3.73  
Leucine Degradation I 3.29  
Xenobiotic Metabolism  
Signaling 
3.08 2.92 
Unfolded protein response 2.93  
eNOS Signaling 2.52  
Aldosterone Signaling in Epithe-
lial Cells 
2.42 2.05 
Glutamine Biosynthesis I 2.42  
Prostate Cancer Signaling 2.25  
Choline Degradation I 2.12  
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Table 3.3: Minor components of AD pathological aggregates identified as 
late- or early-aggregating proteins in C. elegans (reproduced from Fron-
tiers article). 
C. elegans  
entry name 
C. elegans  
Uniprot 
ID 
C. elegans  
gene 
name 
Homo sapiens  
protein name 
Late-
aggregating 
proteins 
   
14331_CAEELx,† P41932 par-5 14-3-3 proteins ß/α; δ 
C1P636_CAEELx,* C1P636 uba-1 
Ubiquitin-like modifier-
activating enzyme 1  
G4S034_CAEELx,* G4S034 spc-1 
Spectrin α-chain, non-
erythrocytic protein 1 
LMN1_CAEELx,* Q21443 lmn-1 Lamin A/C 
Q27473_CAEEL‡,* Q27473 nex-3 Annexin A5 
H4_CAEEL‡ P62784 his-1 
H4 histone family,  
member C 
AT1B3_CAEEL‡ Q9XUY5 nkb-3 
Sodium/potassium-
transporting ATPase 
beta-1 chain 
G5EEG8_CAEELx G5EEG8 frm-1 Band 4.1-like protein 1 
Q95XP6_CAEELx Q95XP6 mca-3 
Plasma membrane Ca++-
transporter ATPase 1 
G3P1_CAEEL‡ P04970 gpd-1 
Glyceraldehyde-3-
phosphate dehydrogen-
ase 
Early-
aggregating 
proteins 
   
GSTP1_CAEELx,+ P10299 gst-1 
Glutathione S-
transferases Mu 3, Mu 5  
DYHC_CAEELx,† Q19020 dhc-1 
Cytoplasmic dynein 1 
heavy chain 1 
HSP90_CAEELx,† Q18688 daf-21 Protein HSP90-β 
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G5ECP9_CAEELx G5ECP9 vab-10 Plectin  
HSP7A_CAEEL‡ P09446 hsp-1 
Heat shock cognate 71 
kDa protein 
KARG2_CAEEL‡ Q27535 ZC434.8 Creatine kinase B-type 
x Minor components identified in both amyloid plaques and NFTs in 
(Ayyadevara, Balasubramaniam, Parcon, et al. 2016). 
† Minor components identified in amyloid plaques in (Liao et al. 2004). 
‡ Minor components identified in NFTs in (Wang et al. 2007). 
* Minor components identified as late aggregating proteins in both day 10 
and day 14. 
+ Minor component identified as early-aggregating protein with a high 
increase in aggregation at both day 10 and day 14. 
 
Figure 3.3: PAR-5 (14-3-3) is highly prone to aggregate at day 10 (repro-
duced from Frontiers article). Representative immunoblot detecting PAR-
5 in insoluble protein extracts from different ages of C. elegans. Right: 
Immunoblot quantification of PAR-5. Band intensities were normalized to 
day 14. N= 4 (biological repeats), SEM depicted. 
3.1.4 Motility analysis and paralysis assay with C. elegans 
overexpressing Aβ in the body-wall muscle 
3.1.4.1 Motility measurements of C. elegans overexpressing Aβ  
In C. elegans, Aβ toxicity in the body-wall muscle causes the ani-
mals to paralyze (Link 1995; McColl et al. 2012). To investigate 
whether a knockdown of early-aggregating proteins that contin-
ued to aggregate strongly at day 10 and day 14 would rescue the 
reduced motility of Aβ overexpressing worms, motility meas-
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urements of worms subjected to different RNAi’s were per-
formed. When comparing wild-type (N2) with Aβ overexpressing 
worms by eye at day 5 (when Aβ overexpressing worms started 
to paralyze at 20°C), worms overexpressing Aβ were obviously 
slower. The motility measurement with the Parallel Worm 
Tracker software did not confirm this observation (Figure 3.4A). 
Next, Aβ overexpressing worms were subjected to two different 
control RNAi’s (GFP and L4440) and RNAi against two different 
early-aggregating proteins with a high increase in aggregation at 
both day 10 and day 14, namely LEC-5 and NEX-1. Animals were 
kept at 20°C and the motility measurements were performed at 
different days (between day 3 and day 6, Figure 3.4B) to analyze 
if a knockdown of LEC-5 or NEX-1 proteins lead to a detectable 
improvement of the motility. With age Aβ overexpressing worms 
were getting slower, which can be demonstrated by the compari-
son of day 4 to day 6 old worms after exposure to GFP RNAi. This 
result could not be confirmed with the second control RNAi. The 
worms subjected to L4440 RNAi showed a significant increase in 
their speed between day 4 and day 6. Also the knockdown of 
NEX-1 resulted to a significant increase of the motility between 
day 3 and day 4 and day 3 and day 6, but no increase could be 
observed when day 4 and day 6 were compared. The knockdown 
of LEC-5 did not lead to a significant difference in motility be-
tween day 3 and day 6. Because the exposure of worms to two 
different control RNAi’s led to contrary results they were not 
compared with the other worms. All measurements were per-
formed with Aβ overexpressing worms kept at 20°C to delay the 
onset of paralysis. But the motility defect was not clear enough 
with age to be detectable by the software.  
Changes in aggregation between day 6 and day 10 are responsi-
ble for seeding, as demonstrated in Figure 3.1C. Therefore, the 
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question whether early-aggregating proteins that continued to 
aggregate strongly at day 10 and day 14 would influence the 
motility of Aβ overexpressing worms arose. The knockdown of 
these proteins and the subsequent motility measurements with 
the Parallel Worm Tracker software did not contribute to answer 
this question.  
 
Figure 3.4: Motility measurements of Aβ overexpressing worms (Aβ OE) 
subjected to different RNAi bacteria.  
A: Average speed with respective SEM of N2 worms and Aβ overexpressing 
worms subjected to OP50. With both strains videos were taken two times 
for 10 min and two times for 20 min at day 5 and the average speeds were 
calculated. Two-tailed p-value: N2 vs. Aβ OE not significant.  
B: Average speed with respective SEM of Aβ overexpressing worms sub-
jected to control RNAi (GFP, L4440) or RNAi against two different early-
aggregating proteins with a high increase in aggregation at both day 10 
and day 14 (LEC-5 or NEX-1). Videos were taken 10 times for 30 s with 
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30 s pauses in between at different days and the average speed was calcu-
lated for each day and each condition. One-way ANOVA: GFP day 4 vs. day 
6 ****p< 0.0001, L4440 day 4 vs. day 6 **p= 0.0032, NEX-1 day 3 vs. day 4 
*p= 0.0427, NEX-1 day 3 vs. day 6 **p= 0.0027.  
3.1.4.2 Paralysis assay of C. elegans overexpressing Aβ and  
PAR-5  
Because the knockdown of aggregating proteins and the subse-
quent motility analysis could not contribute to investigate 
whether aggregating proteins influence Aβ toxicity, an overex-
pression of the late-aggregating protein PAR-5 (C. elegans homo-
log of 14-3-3) was performed. Previously it has been shown that 
a knockdown of PAR-5 rescued paralysis induced by Aβ 
(Ayyadevara, Balasubramaniam, Parcon, et al. 2016). This led to 
the speculation that overexpression of the aggregation-prone 
protein PAR-5 would accelerate the rate of paralysis. Indeed, a 
significant increase in the number of double transgenics para-
lyzed compared to those solely expressing Aβ was observed in 
three biological replicate experiments (Figure 3.5A and data not 
shown). This effect cannot be explained by a general toxicity due 
to PAR-5 overexpression as these animals displayed negligible 
levels of paralysis in the absence of Aβ. Additionally, transgenics 
solely overexpressing Aβ were stained with K114, a Congo red 
analogue that stains amyloid structures (Zhuang et al. 2001), to 
show the formation of Aβ amyloids in the body-wall muscle 
(Figure 3.5B). As already mentioned, seeding activity of 14-3-3 
was demonstrated previously. The data presented here con-
firmed that 14-3-3 accelerated Aβ toxicity. 
Results 
 
68 
 
 
Figure 3.5: Late-aggregation-prone protein PAR-5 (14-3-3) accelerates Aβ 
toxicity in C. elegans. 
A: Paralysis levels of worms that overexpress PAR-5 (PAR-5 OE), Aβ (Aβ 
OE) or both (double transgenic, Aβ OE + PAR-5 OE) (reproduced from 
Frontiers article). Shown are the percentages of worms paralyzed at 
different days. The numbers in the bars represent the total numbers of 
worms analyzed. Fisher’s exact test: Aβ OE vs. Aβ OE + PAR-5 OE, day 3 
*p= 0.032 and day 4 *p= 0.019. 
B: Staining of Aβ aggregates. Paralyzed worms overexpressing Aβ were 
stained at day 2 with K114. Left: Head of a paralyzed worm with Aβ ag-
gregates in the body-wall muscle (box). Right, zoom: Arrows highlight Aβ 
aggregates. Scale bars: Left 10 µm, right: zoom, 3 µm. 
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3.1.5 Insoluble proteins show an increase of specific post-
translational modifications with age in C. elegans 
A number of post-translational modifications (PTMs) have been 
identified in disease-associated aggregates, and a recent study 
detected carbonylation in the mouse age-dependent insoluble 
proteome (Tanase et al. 2016). Therefore, it is possible that 
PTMs occurring with age influence the seeding ability of late-
aggregating proteins as well as early-aggregating proteins that 
continue to become more insoluble with age. Western blot anal-
ysis confirmed that detergent-insoluble proteins show an in-
crease of ubiquitination (Figure 3.6A, right) and phosphorylation 
of tyrosines (Figure 3.6B, right) with age in C. elegans. The in-
crease in PTMs was stronger compared to the increase in insolu-
bility with age for all proteins, shown by the total protein stain-
ing (Figure 3.6A and B, left part). Regarding the soluble proteins 
no obvious differences in PTMs between young (day 2) and old 
(day 14) worms can be detected (Figure 3.6A and B, right part). 
These results were confirmed with a second repeat with protein 
extracts from another timeline. Additionally, dimethylation of 
arginines, citrullination (irreversible conversion of arginine into 
citrullin) and phosphorylation of serines and threonines were 
analysed, but no differences with age could be detected. Howev-
er, only a few faint bands were visible (data not shown).  
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Figure 3.6: Insoluble proteins show an increase of post-translational modi-
fications (PTMs) with age in C. elegans.  
Left: Blot of soluble and insoluble protein extracts from young (day 2) and 
old (day 14) worms stained with Sypro Ruby protein blot stain. Right: 
Immunoblot detecting A: ubiquitinated proteins (mono- and poly-
ubiquitin) or B: proteins with phosphorylated tyrosine in soluble and 
insoluble protein extracts from young (day 2) and old (day 14) worms. 
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3.1.6 Aged mouse brains contain protein aggregates that 
seed Aβ aggregation in vitro 
To confirm that insoluble proteins present in mammals also have 
the potential to seed Aβ aggregation, the same in vitro assay as 
described above was performed with homogenates of wild-type 
mouse brains. Of note, previous studies did not detect seeding 
activity in aged wild-type mouse brains (Fritschi et al. 2014; 
Nagarathinam et al. 2013). However, total brain homogenates 
were tested without any enrichment for insoluble proteins. Here, 
detergent-insoluble protein extracts from young (2-3 months) 
and aged (18-20 months) mouse brains were measured. Com-
pared to young extracts, insoluble protein extracts from aged 
mouse brains led to a significant decrease of the lag time preced-
ing Aβ aggregation (Figure 3.7, p= 0.0073). No further increase 
in seeding potential was detected when examining insoluble 
extracts from 25-28 month old mice (Figure 3.7, p= 0.0067 com-
pared to 2-3 months). This is consistent with the similar seeding 
activity of insoluble protein extracts from late-middle aged and 
old C. elegans. For comparison, the insoluble extract from an 
APP23 transgenic mouse, which contains Aβ seeds, and the solu-
ble extract from an aged wild-type mouse brain were included. 
Collectively, these results demonstrate, that cross-seeding of Aβ 
aggregation by age-dependent protein aggregation is conserved 
from C. elegans to mammals. 
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Figure 3.7: Insoluble protein extracts from aged wild-type mouse brains 
seed Aβ aggregation in vitro (reproduced from Frontiers article). Lag 
times measured for Aβ aggregation in the presence of 0.001 μg detergent-
insoluble protein extracts from wild-type mouse brains at different ages. 
Mean values (red lines) with respective SEM of three biological replicates 
(each including five technical replicates) from on average 2.7 month-, 18.7 
month- and 26.7 month-old mouse brain insoluble extracts. Lag time of an 
18 month-old mouse brain soluble extract (sol, negative control) and a 20 
month-old mouse brain insoluble extract from an APP23 transgenic 
mouse (APP23, positive control). One-way ANOVA: 2.7 months vs.  18.7 
months **p= 0.0073, 2.7 months vs.  26.7 months **p= 0.0067. 
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3.1.7 Formation of Aβ plaques in APP23 transgenic mouse 
brains after injection of insoluble proteins from aged 
mouse brains  
To analyze whether insoluble proteins can also seed Aβ aggrega-
tion in vivo, detergent-insoluble proteins from young or old wild-
type mouse brains were injected into the hippocampus of young 
(3 months of age) APP23 transgenic mice. In transgenic mouse 
models, injection of whole brain extracts containing Aβ seeds is 
sufficient to lead to the formation and spreading of Aβ plaques 
(Kane et al. 2000; Meyer-Luehmann et al. 2006), whereas after 
injection of whole brain extracts from control patients without 
AD or wild-type mice no Aβ plaques were observed. An extract 
containing an enrichment of insoluble proteins from wild-type 
mouse brains was not analyzed so far. Six months after injection 
of detergent-insoluble proteins from 18.3 month-old wild-type 
mouse brains, the formation of Aβ plaques can be observed in 
three out of five mice (Figure 3.8, left). Injection of insoluble 
proteins from young mouse brains (2.5 months) did not lead to 
plaque formation (Figure 3.8, right). Only in one mouse a possi-
ble plaque formation can be seen (Figure 3.8 zoom, blue arrow). 
These results suggest, that insoluble proteins from old wild-type 
mouse brains seed Aβ aggregation in vivo although only a few 
plaques were observed.  
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Figure 3.8: Insoluble protein extracts from aged wild-type mouse brains 
seed Aβ aggregation in vivo. 
Left: Hippocampi of five APP23 transgenic mice injected with insoluble 
protein extracts from 18.3 month old mice.  
Middle: Zoom, formation of Aβ plaques. Red arrows indicate plaques de-
veloped after injection of insoluble protein extracts from old mice, blue 
arrow indicates possible plaque formation after injection of insoluble 
protein extracts from young mice. 
Right: Hippocampi of four APP23 transgenic mice injected with insoluble 
protein extracts from 2.5 month old mice (control).  
All mice were three months of age when injected and were histologically 
analyzed six months after injection. 
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3.1.8 Identification of insoluble proteins in wild-type mouse 
brains 
Because of the demonstrated seeding potential of proteins that 
were highly insoluble with age, a quantitative mass spectrometry 
study was performed to identify the change in aggregation with 
age of the insoluble proteins in wild-type mouse brains. Deter-
gent-insoluble proteins of three young (2.7 months on average) 
and three old (18.7 months on average) wild-type mouse brains 
were probed with heavy or light dimethyl-labeling to analyze 
whether each protein shows an increase or decrease in insolubil-
ity with age (total protein staining of the analyzed protein ex-
tracts is shown in Figure 3.9). During one measurement insolu-
ble protein extracts from one young mouse brain and from one 
old mouse brain were compared. 617 quantifiable aggregation-
prone proteins were identified in all three biological replicates. 
Figure 3.10A shows a comparison of the log2-transformed ratios 
of insoluble proteins from young versus old mice between each 
replicate. Because the ratios are normalized, only changes in 
insolubility with age versus the mean change can be analyzed. 
With the data presented here, just a few changes compared to 
the mean can be observed. To analyze if the replicates can be 
correlated to each other, the log2-transformed ratios of each 
insoluble protein from young mice versus old mice of two repli-
cates were plotted against each other (Figure 3.10B-D). Inde-
pendent of which replicates were compared no close correlation 
could be detected (Spearman r< 0.15). Already the total protein 
staining of the different insoluble protein extracts shows a high 
variability within the young mice and the old mice (Figure 3.9). 
Comparing two young mice with two aged mice, an increase in 
insolubility with age can be detected (Figure 3.9, left), but be-
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tween another young and old mouse a decrease can be seen 
(Figure 3.9, right).  
We identified 14 proteins within the top 25th percentile in all 
three replicates, i.e. with the highest change in aggregation with 
age. To analyze which proteins have the potential to seed Aβ 
aggregation, a knockdown of homologs of these mouse brain 
proteins in C. elegans in Aβ overexpressing worms and a subse-
quent motility analysis should be performed. 12 C. elegans homo-
logs were identified. Interestingly, one of these proteins was 
TDP-1 (C. elegans homolog of TDP-43). TDP-43 has already been 
shown to cross-seed Aβ (Fang et al. 2014). But immunoblot de-
tection with a TDP-43 antibody did not confirm the change in 
aggregation with age (data not shown). To analyze if a knock-
down of homologs of mouse brain proteins with the highest in-
crease in insolubility with age could influence the motility of Aβ 
overexpressing worms, a first experiment was performed with 
different control RNAi’s and two different motility analysis pro-
grams (Appendix Table 6.1). During the comparison of minimum 
and maximum speeds of the worms subjected to control RNAi’s a 
big difference within one control can be detected (for example a 
six-fold difference between minimum and maximum speed for 
HER-1 independently of the analysis program). For some videos 
only a few worms could be detected and analyzed by the pro-
grams. Even the adjustment of the parameters did not improve 
the analysis. Because the measurements with different control 
RNAi’s were not reproducible, the motility analysis was not con-
tinued and the question whether proteins with the highest 
change in insolubility with age in mouse brains could be respon-
sible for seeding Aβ aggregation could not be answered.   
Results 
 
77 
 
 
Figure 3.9: Total protein staining of insoluble protein extracts from young 
and old mice stained with Sypro Ruby protein blot stain. 
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Figure 3.10: Quantitative mass spectrometry results of insoluble proteins 
of brains from young (2.7 months) versus old (18.7 months) mice. Three 
replicates with one insoluble protein extract from a young mouse brain 
and one insoluble protein extract from an old mouse brain each were 
measured.  
A: Log2 ratio of insoluble proteins from young mouse brains versus old 
mouse brains for each replicate. Each point represents the ratio of one 
protein. 
B-D: Correlation of log2 ratio of insoluble proteins from young mouse 
brains versus old mouse brains between the different replicates.  Each 
point represents the ratio of one protein. B: Spearman r= 0.1475, C: 
Spearman r= -0.1454, D: Spearman r= 0.1349.  
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3.1.9 Summary 
To summarize, it was shown in 3.1 that age-dependent protein 
aggregates can initiate Aβ aggregation and that this cross-
seeding is conserved from nematodes to mammals. One of the 
late-aggregating proteins that is also a minor component in AD 
pathological aggregates, 14-3-3 (PAR-5), was demonstrated to 
enhance paralysis of worms overexpressing Aβ and PAR-5. 
Moreover, an increase in specific PTMs was detected in insoluble 
proteins with age in C. elegans.  
3.2 Investigation whether rapidly-aggregating proteins 
seed the aggregation of other proteins 
In parallel to the finding that age-dependent protein aggregates 
seed the aggregation of Aβ, as demonstrated in 3.1, our goal was 
to investigate whether rapidly-aggregating proteins could lead to 
the aggregation of other non-disease related proteins in C. ele-
gans. The idea was to chemically crosslink an early-aggregating 
protein, identified in 3.1.3, together with its co-aggregating pro-
teins, to purify them and to identify them by mass spectrometry.  
During the preparation of the C. elegans samples for the mass 
spectrometry analysis and the evaluation of the mass spectrome-
try results described in 3.1, a tandem-affinity purification strate-
gy in denaturing conditions was established to isolate and identi-
fy rapidly-aggregating proteins together with their co-
aggregates. The aggregation-prone protein RHO-1, a Rho GTPase 
orthologous to transforming protein RhoA in mammals, is 
known to aggregate fast when it is overexpressed in C. elegans 
(already at day 1). RHO-1 was tagged with a tandem-affinity tag 
combining a histidine tag (hexa-histidine) for Nickel affinity 
purification with a biotinylation sequence (avidin tag) for subse-
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quent avidin purification (Schaffer et al. 2010; Tagwerker et al. 
2006). The avidin tag is an artificial target motif for biotinylation 
by the E. coli biotin holoenzyme synthetase birA (Schaffer et al. 
2010). To be able to purify protein aggregates, denaturing condi-
tions (8 M urea) were needed. Therefore, the tandem-affinity tag 
was chosen, because it tolerates two-step purification under fully 
denaturing conditions (Tagwerker et al. 2006). The first purifica-
tion step was shown to efficiently remove endogenous biotinyl-
ated proteins. With the second purification step with avidin 
beads, highly purified samples should be achieved because of the 
high affinity between biotin and avidin. The avidin tag published 
by (Schaffer et al. 2010) was used for the study presented here, 
because they demonstrated a succesfull purification of proteins 
with the avidin tag from C. elegans lysates and the subsequent 
mass spectrometry analysis. Additionally, the worms expressed 
birA under the same promoter as the tagged protein. Therefore, 
tissue specificity is obtained and proteins could be selectively 
purified from a target cell type. To collect large numbers of indi-
viduals, C. elegans overexpressing the tagged RHO-1 together 
with the biotinylation enzyme birA were cultured in liquid. We 
postulated that during aging the rapidly-aggregating protein 
(potential seeding protein) co-aggregates with other proteins. To 
identify the co-aggregating proteins, our plan was to remove the 
detergent-soluble proteins from a homogenate of worms over-
expressing the tagged RHO-1 and chemically crosslink the deter-
gent-insoluble proteins (Figure 3.11). RHO-1 together with the 
crosslinked proteins would then be solved in urea and purified 
with Nickel affinity chromatography to be able to identify the 
proteins by mass spectrometry in the end.  
Results 
 
81 
 
 
Figure 3.11: Schematic showing the procedure of chemical crosslinking of 
rapidly-aggregating proteins (red) (tagged with a histidine-avidin tag) 
with their co-aggregating proteins (blue), the subsequent purification, 
digestion with trypsin and identification of tryptic peptides with mass 
spectrometry.  
3.2.1 Purification of RHO-1 without crosslinking  
3.2.1.1 Purification with imidazole 
To establish the purification protocol for rapidly-aggregating 
proteins, RHO-1 without crosslinking was purified with Nickel 
affinity chromatography using a high imidazole concentration in 
the elution buffer as it is recommended for the purification with 
the nickel column. Figure 3.12 shows an immunoblot of the first 
purification of RHO-1 detecting biotinylated avidin of the histi-
dine-avidin tag of RHO-1 in the fraction, that was loaded onto the 
column (load), in the fractions that were collected during the 
sample was loaded (flow through) and during the column was 
washed (wash) and in the elution fractions (number three to 
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number nine). Because a high protein amount of RHO-1 can be 
detected in the flow through fractions, a lot of RHO-1 did not 
bind to the column. One possibility is that the protein amount 
was too high so that the column could not bind additional pro-
teins anymore. Moreover, it can be seen that RHO-1 was washed 
away from the column, which means that it was not bound 
properly. Performing the elution with a linear gradient to a high 
imidazole concentration resulted to a broad elution peak with 
many fractions containing RHO-1. It seemed like RHO-1 was 
continuously washed and eluted from the column. Most of RHO-1 
was eluted with 28% elution buffer (145 mM imidazole, fraction 
number E6).  
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Figure 3.12: Purification with Nickel affinity chromatography of RHO-1 
with histidine-avidin tag. Elution was performed with a linear gradient to 
500 mM imidazole. Shown is an immunoblot detecting biotinylated avidin 
in the collected fractions. Load: Insoluble protein extract from C. elegans 
overexpressing RHO-1 that was loaded on the column. Flow through: First 
two out of 20 fractions that were collected during the extract was loaded 
on the column. Wash: First two out of 10 fractions that were collected 
during the column was washed. Elution: Seven out of 20 eluted samples. 
E3 to E9: Elution fractions number three to nine. Arrow: RHO-1 with histi-
dine-avidin tag. 
3.2.1.2 Purification under harsh conditions 
Because the first purification of RHO-1 with a high imidazole 
concentration in the elution buffer led to a broad elution of RHO-
1, a different purification was used to establish the purification 
protocol for rapidly-aggregating proteins. RHO-1 without cross-
linking was purified with Nickel affinity chromatography using a 
harsh elution buffer published by (Tagwerker et al. 2006). They 
state that stringent purification conditions remove non-
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crosslinked, interacting proteins. Therefore, unspecific binding is 
reduced. Figure 3.13A shows an immunoblot with the collected 
fractions of the purification of RHO-1 with the published buffers. 
In Figure 3.13B a silver stained SDS gel of another purification 
with the same conditions can be seen. Because there is less RHO-
1 in the flow through fractions visible, a lot of RHO-1 was bound 
to the column. Moreover, most of RHO-1 can be eluted in only 
two fractions with the harsh elution buffer. The elution fractions 
were very pure, because there were only a few other faint bands 
visible (Figure 3.13B). Most of RHO-1 was eluted with 83% or 
78% elution buffer (Figure 3.13A fraction number E17 or Figure 
3.13B fraction number E16). In general, this second purification 
protocol seemed to be useful to purify rapidly-aggregating pro-
teins. 
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Figure 3.13: Purification with Nickel affinity chromatography of RHO-1 
with histidine-avidin tag. Elution was performed with a linear gradient 
and harsh conditions (elution buffer with 2% SDS, 10 mM EDTA, 100 mM 
Tris pH 4.3). Load: Insoluble protein extract from C. elegans overexpress-
ing RHO-1 that was loaded on the column. Flow through: First two out of 
20 fractions that were collected during the extract was loaded on the 
column. Elution: Two out of 20 eluted samples. Arrow: RHO-1 with histi-
dine-avidin tag. 
 A: Immunoblot detecting biotinylated avidin in the collected fractions. 
E16, E17: Elution fractions number 16 and 17.  
B: Silver stained SDS gel with collected fractions of another purification. 
E15, E16: Elution fractions number 15 and 16. 
3.2.2 Purification of RHO-1 crosslinked with 0.4% Para-
Formaldehyde (PFA) 
After the establishment of the purification protocol under harsh 
conditions, RHO-1 was crosslinked with 0.4% Para-Formaldehye 
(PFA), which is a common crosslinker and very reactive towards 
Results 
 
86 
 
primary amines. But two different problems appeared. First, 
crosslinked RHO-1 could not be eluted from the column (Figure 
3.14A and B). The immunoblot detection shows only faint bands 
in the elution fractions (Figure 3.14A). With a silver staining only 
some bigger proteins (~ 60 kDa) are visible (Figure 3.14B). Even 
with the harsh elution buffer, RHO-1 was still bound to the col-
umn. 
To investigate what happened with RHO-1 after crosslinking, 
resolving in urea and centrifugation, the final pellet (not solubil-
ized by urea) was compared with the final pellet without cross-
linking of RHO-1 and the following second problem was detect-
ed: A lot of RHO-1 remained in the urea-insoluble pellet fraction 
compared to the fraction without crosslinking (Figure 3.14C). 
Therefore, it is likely that most of RHO-1 becomes so insoluble 
after crosslinking that it cannot be disrupted by urea.  
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Figure 3.14: Purification with Nickel affinity chromatography of RHO-1 
with histidine-avidin tag crosslinked with 0.4% PFA. Elution was per-
formed with a linear gradient and harsh conditions (elution buffer with 
2% SDS, 10 mM EDTA, 100 mM Tris pH 4.3). A-B: Load: Crosslinked insol-
uble protein extract from C. elegans overexpressing RHO-1 that was load-
ed on the column. Flow through: First two out of 20 fractions that were 
collected during the extract was loaded on the column. Elution: Four out 
of 20 eluted samples. Arrow: RHO-1 with histidine-avidin tag. 
 A: Immunoblot detecting biotinylated avidin in the collected fractions.   
B: Silver stained SDS gel with collected fractions. 
C: Immunoblot detecting biotinylated avidin in the urea-insoluble pellet 
from the insoluble protein extraction after crosslinking and centrifugation 
(+) or in the urea-insoluble pellet without crosslinking (-).  
3.2.3 Purification of RHO-1 crosslinked with Disuccinimidyl 
glutarate (DSG) 
Because the crosslinking with PFA prevented the solubilisation 
of aggregated RHO-1 proteins in urea, we investigated whether 
another crosslinker would be more appropriate. Disuccinimidyl 
glutarate (DSG) reacts with primary amines on the N-termini and 
ε-amine of lysine residues forming an amide bond. Concentra-
tions between 0.25 mM and 0.0025 mM were used. The cross-
linked detergent-insoluble protein extracts and the urea-
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insoluble pellets were analysed with an immunoblot, shown in 
Figure 3.15. The lowest protein amount of detergent-insoluble 
proteins and the highest protein amount in the urea-insoluble 
pellet were detected in the sample with the highest DSG concen-
tration suggesting too high crosslinking similar to the results 
with PFA. When comparing the sample without crosslinking with 
the samples with low DSG concentrations, no difference can be 
seen, which raised the question whether the crosslinking did not 
work with low concentrations. Therefore, a purification was 
performed with the extract crosslinked with the highest concen-
tration (0.25 mM DSG), but no improvement could be detected in 
comparison to the treatment with PFA. Nothing could be seen in 
the elution fractions, which suggests that RHO-1 could not be 
eluted from the column (Figure 3.16) and there was still a high 
amount of RHO-1 in the urea-insoluble pellet fraction, as already 
shown in Figure 3.15B.   
 
 
 
Results 
 
89 
 
 
Figure 3.15: Immunoblots detecting biotinylated avidin of histidine-avidin 
tag of crosslinked RHO-1. Arrow: RHO-1 with histidine-avidin tag. 
A: Detergent-insoluble protein extracts from C. elegans overexpressing 
RHO-1 after crosslinking with different concentrations of DSG or without 
crosslinking (-).  
B: Urea-insoluble pellet from the insoluble protein extraction after cross-
linking with different concentrations of DSG or without crosslinking (-).  
 
Results 
 
90 
 
 
Figure 3.16: Purification with Nickel affinity chromatography of RHO-1 
with histidine-avidin tag crosslinked with 0.25 mM DSG. Elution was per-
formed with a linear gradient and harsh conditions (elution buffer with 
2% SDS, 10 mM EDTA, 100 mM Tris pH 4.3). Shown is an immunoblot 
detecting biotinylated avidin in the collected fractions. Load: Crosslinked 
insoluble protein extract from C. elegans overexpressing RHO-1 that was 
loaded on the column. Flow through: First two out of 20 fractions that 
were collected during the extract was loaded on the column. Elution: Nine 
out of 20 eluted samples. Arrow: RHO-1 with histidine-avidin tag. 
3.2.4 Summary 
To summarize, RHO-1 aggregates solved in urea can be purified 
with Nickel affinity chromatography using a harsh elution buffer. 
After crosslinking of RHO-1 it could not be eluted from the col-
umn anymore under harsh conditions independent of the type 
and the amount of the crosslinker. Moreover, with increasing 
amounts of crosslinker most of RHO-1 becomes so insoluble that 
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it cannot be disrupted by urea. Because the problems with the 
crosslinking of RHO-1 could not be solved, we were not able to 
analyze co-aggregating proteins.  
Discussion 
 
92 
 
4 Discussion 
4.1 Identifying age-dependent heterologous seeds for 
amyloid-β aggregation 
This chapter includes a part of the discussion reproduced from: 
Groh N, Bühler A, Huang C, Li KW, van Nierop P, Smit AB, 
Fändrich M, Baumann F and David DC (2017) Age-Dependent 
Protein Aggregation Initiates Amyloid-β Aggregation. Front. 
Aging Neurosci. 9:138. Doi: 10.3389/fnagi.2017.00138 
The discovery of widespread protein aggregation with age has 
raised the question whether these assemblies influence disease-
related protein aggregation. The study described here demon-
strates, that a direct interaction between insoluble proteins from 
aged C. elegans or aged mouse brains initiates Aβ aggregation in 
vitro. These results could have important implications for our 
understanding of the initial pathogenesis steps in AD, particular 
in late-onset cases.  
A recent study revealed that wild-type spinal cord homogenates 
injected into transgenic mice expressing α-synuclein with the 
A53T mutation induced early α-synuclein pathology (Sacino et 
al. 2016). As cortical homogenates from wild-type mice had no 
effect, the authors speculate that higher levels of myelinated 
white matter in the spinal cord could be responsible. A myelin 
component is unlikely to be the seeding agent in the data pre-
sented here. First, a very stringent procedure was performed to 
isolate highly-insoluble proteins while removing the lipids using 
sucrose flotation and then high concentrations of strong deter-
gents including SDS. Second, brain homogenates without spinal 
cord, brain stem and cerebellum were used. Third, the effect 
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observed is age-dependent and therefore unlikely to be due to 
the basic composition of the brain tissue used. Fourth, numbers 
of oligodendrocytes decrease with age (Pelvig et al. 2008). 
Therefore, it is reasonable to conclude that the induction of Aβ 
seeding in the present study is due to highly-insoluble proteins 
rather than a lipid contaminant. In addition, the findings pre-
sented here cannot be explained by age-related changes in en-
dogenous Aβ (Mahler et al. 2015) as C. elegans lack homologs of 
BACE and no Aβ-like peptides have been detected. 
Previous in vitro studies have shown cross-seeding between Aβ 
and other disease-associated aggregating proteins including α-
synuclein, scrapie prion protein (PrPSc), human islet amyloid 
polypeptide (hIAPP), tau and TAR DNA-binding protein 43 (TDP-
43) (Fang et al. 2014; Morales, Moreno-Gonzalez, and Soto 2013; 
Vasconcelos et al. 2016). Interestingly, acetylcholinesterase, a 
minor component in Aβ plaques, was also shown to accelerate 
Aβ aggregation in vitro (Inestrosa et al. 1996). This raised the 
possibility that minor components in disease-associated aggre-
gates could also play a role in seeding the main component. Re-
cently, this hypothesis has gained support with the discovery 
that these minor components are significantly over-represented 
in the age-dependent insoluble proteome (David et al. 2010). 
Therefore, a large number of minor components are themselves 
aggregation-prone. The present data support the notion that 
misfolding and aggregation of minor components during age 
constitute heterologous seeding events for disease-associated 
aggregation. A recent study examined the expression levels of 
minor components found in plaques and NFTs in healthy brains 
(Freer et al. 2016). Interestingly, the regions known to be the 
first affected by NFT pathology in AD displayed higher levels of 
these minor aggregate components compared to non-affected 
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regions. Of the 16 minor components identified as late- or early-
aggregating proteins in the analysis presented here, seven out of 
10 evaluated in the study by (Freer et al. 2016) followed this 
pattern. Therefore, it is possible that higher levels of age-
dependent seeds accumulate in these regions and induce tissue-
specific vulnerability to disease protein aggregation in AD. Over-
all, it will be important to determine which proteins and in which 
locations have seeding activity.  
The presented proteomic timeline analysis highlights several 
minor plaque or NFT components that should be prime candi-
dates as initiators of Aβ or tau seeding events to be investigated 
in future studies. One of these candidates, 14-3-3, has already 
been confirmed as a heterologous seed for tau aggregation (Li 
and Paudel 2016). It was also shown that a knockdown of 14-3-3 
rescued Aβ toxicity in C. elegans (Ayyadevara, Balasubramaniam, 
Parcon, et al. 2016). Importantly, the present study shows that 
14-3-3 overexpression accelerated Aβ toxicity in a C. elegans 
model for Aβ aggregation. With a staining of these paralyzed 
double-transgenic worms with an amyloid-specific dye (K114) 
or an Aβ-specific antibody (6E10) no obvious difference in the 
abundance of Aβ was detected compared to the staining of 
worms solely overexpressing Aβ (data not shown). However, the 
staining was variable between worms in each strain. A quantifi-
cation of the fluorescence intensity was also not possible, be-
cause of the high background. To analyze whether paralyzed 
worms overexpressing Aβ together with the C. elegans homolog 
of 14-3-3 (PAR-5) have more Aβ aggregates than worms solely 
overexpressing Aβ and whether a co-localization of Aβ and PAR-
5 could be observed, the staining has to be improved. In addition, 
we did not see any obvious differences in the insoluble Aβ levels 
detected by western blot. For the future, the next step would be 
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to analyze whether insoluble protein extracts of worms overex-
pressing PAR-5 accelerate the aggregation of Aβ in vitro. Moreo-
ver, it would be interesting to perform an in vitro tau seeding 
assay to analyze whether detergent-insoluble protein extracts 
from aged wild-type individuals can also seed the aggregation of 
tau in vitro.   
Another possibility to explain why insoluble proteins become 
effective seeds with age is that changes in the structure of these 
proteins could occur. It would be interesting to analyze whether 
minor plaque or NFT components, which were identified as late-
aggregating proteins, are in an amyloid state.  
As some seeding proteins may not be sufficiently abundant to be 
detected in disease aggregates, it will be relevant to investigate 
the other late-aggregating proteins as well as early-aggregating 
proteins that continue to become more insoluble with age. With 
a first analysis presented here we wanted to investigate whether 
a knockdown of two different early-aggregating proteins that 
continued to aggregate strongly at day 10 and day 14 (NEX-1 and 
LEC-5) would rescue the reduced motility of Aβ overexpressing 
worms. But motility measurements at different time points of Aβ 
overexpressing worms subjected to RNAi against NEX-1 or LEC-5 
with the Parallel Worm Tracker software (Ramot et al. 2008) led 
to contrary results. Already for the controls different results 
were obtained, with one control showing a decrease in motility 
with age as expected and one showing an increase. The main 
problem was, that very often only a few worms were detected 
automaticaly by the software. This resulted to big differences in 
speed between the single tracks and less reproducibility. We 
tried to adjust the minimum and maximum size of an object that 
will be identified as a single worm, as suggested in the publica-
tion. But even the adjustment of the software parameters did not 
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improve the detection of the worms. The reason why we wanted 
to establish a motility assay was to be able to analyze a lot of 
different conditions in short time. For the assay Aβ overexpress-
ing worms were used that were kept at 20°C to delay the onset of 
paralysis, but the motility defect was not clear enough with age. 
The model is only useful to study paralysis rates after switching 
the worms to 25°C at day 1. Because the worms start to paralyze 
one day after the temperature shift, we are not able to see effects 
of preventing age-dependent protein aggregation by RNAi. Still, 
it would be interesting to continue with the analysis of late-
aggregating proteins (and also early-aggregating proteins that 
continue to become more insoluble with age). In particular, pro-
teins associated with the eight pathways highlighted by the IPA 
analysis should be promising candidates. For future studies a 
paralysis assay could be performed as demonstrated for the 
worms overexpressing Aβ and PAR-5. Therefore, double-
transgenic worms overexpressing Aβ and one of the candidates 
need to be generated to analyze whether an increase in paralysis 
can be seen. Then the respective protein would be a good candi-
date for a dangerous aggregating protein that seed Aβ aggrega-
tion.  
Moreover, the finding that aggregating proteins co-localize 
would help to demonstrate that they interact with each other. To 
analyze whether co-localization between Aβ and an inherent 
aggregating protein in C. elegans could be observed, strains ex-
pressing Aβ and a protein that is known to aggregate in the 
body-wall muscle should be generated. Preliminary results sug-
gest that low numbers of Aβ aggregates and variability between 
animals will make the analysis challenging (data not shown).  
Another point that should be considered is the possibility that 
post-translational modifications (PTMs) occurring with age in-
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fluence the seeding ability of late-aggregating proteins as well as 
early-aggregating proteins that continue to become more insolu-
ble with age. A number of PTMs have been identified in disease-
associated aggregates, and a recent study detected carbonylation 
in the mouse age-dependent insoluble proteome (Tanase et al. 
2016). (Tanase et al. 2016) determined, that PTMs are conduc-
tive of aggregate formation. PTMs could lead to unfolding of 
proteins and exposure of their hydrophobic sites which increas-
es their tendency to aggregate. In humans, phosphorylation of 
tyrosine residues, catalyzed by tyrosine kinases, plays a role in 
cellular signal transduction (as described in the human metabo-
lome database (Wishart et al. 2013)). Phosphorylation of tyro-
sines of proteins with age could change their structural stability 
leading to their unfolding and at least to their aggregation.  
Ubiquitination directs proteins for degradation by the pro-
teasome or by lysosomes (as described in 1.). Ubiquitinated un-
folded proteins often assemble in large aggregates. The present 
data demonstrate by western blot analysis, that insoluble pro-
teins from C. elegans show an increase in phosphorylation of 
tyrosines and ubiquitination with age. Moreover, three other 
PTMs were analyzed: dimethylation of arginines, citrullination 
(irreversible conversion of arginine into citrullin) and phosphor-
ylation of serines and threonines. No difference could be detect-
ed. However, only a few faint bands were visible. Either the 
western blot protocol has to be improved or different antibodies 
should be tried out. For the future it would be interesting to ana-
lyze whether other PTMs could be detected or whether these 
findings could be confirmed with the insoluble proteins of mouse 
brains. Besides the identification of changes in aggregation with 
age of the insoluble mouse brain proteome by mass spectrome-
try as discussed later, changes in PTMs with age could be ana-
lyzed. For the PTM analysis of insoluble proteins of young and 
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aged mouse brains by mass spectrometry, the results presented 
here cannot be used, because the methodology to analyze PTMs 
is different including an enrichment strategy of the proteins or 
peptides. 
Because of the demonstrated seeding potential of highly insolu-
ble proteins from aged mouse brains, we performed a quantita-
tive mass spectrometry study of young and aged wild-type 
mouse brains to identify the change in aggregation with age of 
the insoluble proteome. Overall, there was no general increase in 
insolubility with age and our results suggest variabilities in the 
insoluble protein fraction preparation. After normalization, we 
found very little correlations between fold changes in levels of 
insoluble proteins between the three replicates. This is similar to 
the previous findings where only a limited number of proteins 
changing their insolubility with age was observed (Ottis et al. 
2013). (Ottis et al. 2013) demonstrated, that absolute changes in 
the levels of insoluble proteins of hippocampal proteomes from 
rats were small compared to the findings in the whole C. elegans 
insoluble proteome. Moreover, (Walther and Mann 2011) per-
formed a proteomic analysis of three brain regions as well as 
heart and kidney in mice aged five or 26 months without any 
enrichment for insoluble proteins. They showed that mean pro-
tein abundance changes of more than twofold between young 
and old mice were detected in less than 1% of all proteins and 
very few of these were statistically significant. Still, to continue 
with the mass spectrometry results presented here, 14 proteins 
that aggregate the most with age in all three replicates were 
determined with 12 homologues in C. elegans. One of the identi-
fied proteins was TDP-43. Inclusions of TDP-43 are hallmarks of 
frontotemporal lobar dementia (FTLD) and amyotrophic lateral 
sclerosis (ALS). Intriguingly, human TDP-43 was shown to form 
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oligomers that cross-seed Aβ to form amyloid oligomers (Fang et 
al. 2014). Because these proteins seemed to be interesting can-
didates for seeding, the goal was to perform a motility analysis of 
Aβ overexpressing worms subjected to RNAi against homologues 
of all 12 proteins. During the first experiment only worms sub-
jected to control RNAi's were analyzed with two different motili-
ty analysis programs. The measured speeds were variable and 
not reproducible within the same group and differed between 
the worms subjected to different control RNAi's independent of 
the software used, as discussed previously. Therefore, the analy-
sis was not continued with the candidates.  
An important aspect to be addressed was to determine the seed-
ing activity of age-dependent protein aggregation in vivo. There-
fore, an established mouse model for Aβ seeding was used, in 
which past experiments showed that intracerebral injection of 
Aβ-rich brain extracts in young APP-transgenic mice induced Aβ 
plaque formation prior to the appearance of endogenous Aβ 
deposits (Meyer-Luehmann et al. 2006). In the present study 
insoluble protein extracts from aged mouse brains were injected. 
After six months the formation of some Aβ plaques was observed 
in three out of five mice. Of note, it was unclear whether this in 
vivo model would be sufficiently sensitive to detect heterologous 
seeding by the age-dependent insoluble proteome within the 
time window preceding the emergence of endogenous plaques 
and cerebral amyloid-β angiopathy. Indeed, the low amount of 
detected Aβ plaques could be explained by the in vitro data 
showing a reproducible but relatively low seeding activity com-
pared to Aβ seeds and therefore successful in vivo seeding stud-
ies may require repeated injections of insoluble extracts and/or 
very long incubation times. 
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In summary, the study described here shows that protein aggre-
gates formed during normal aging in C. elegans and in mouse 
brains initiate Aβ aggregation in vitro. In agreement with the late 
onset of neurodegeneration in humans, cross-seeding activity 
appears in the later stages of life in C. elegans. The study demon-
strates that several minor components identified previously in 
NFTs and amyloid plaques in AD are prone to aggregate with 
age. Additionally, overexpression of one of these proteins, PAR-5 
(C. elegans homolog of 14-3-3), accelerates Aβ toxicity in C. ele-
gans.  
Together, the present findings emphasize the need to under-
stand better why protein insolubility is prevalent in older age 
and how the cellular quality-control systems fail to prevent it. 
Abrogating the formation of heterologous seeds could signifi-
cantly reduce disease-associated seeding events and delay the 
onset of AD. As perspective it would be interesting to map the 
aggregating proteome throughout the brain in healthy individu-
als and in patients with neurodegeneration to clarify whether 
aging seeds associate with specific disease types in specific ana-
tomical areas. 
4.2 Investigation whether rapidly-aggregating proteins 
seed the aggregation of other proteins 
A variety of neurodegenerative diseases are associated with the 
aggregation of specific proteins. Moreover, aging is a major risk 
factor for neurodegeneration. In recent years protein aggrega-
tion with age, in the absence of disease, has been investigated by 
several groups (David et al. 2010; Reis-Rodrigues et al. 2012; 
Walther et al. 2015). In parallel to the first study presented here, 
showing that age-dependent protein aggregates seed the aggre-
gation of Aβ (3.1), a second study was performed to investigate 
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whether rapidly-aggregating proteins lead to the aggregation of 
other non-disease related proteins in C. elegans. Our goal was to 
crosslink proteins in an aggregate, purify them in denaturing 
conditions and to identify the co-aggregating proteins by mass 
spectrometry. Finally, we intended to quantify changes in co-
aggregating proteins with age. To establish the protocol for tan-
dem-affinity purification under denaturing conditions for the 
isolation and identification of rapidly-aggregating proteins with 
co-aggregating proteins, an aggregation-prone protein was used. 
RHO-1, a Rho GTPase orthologous to transforming protein RhoA 
in mammals, is known to aggregate fast when it is overexpressed 
in C. elegans. Therefore, transgenic worms were generated over-
expressing RHO-1 tagged with a tandem-affinity tag combining a 
histidine tag for Nickel affinity purification with a biotinylation 
sequence (avidin tag) for subsequent avidin purification 
(Schaffer et al. 2010; Tagwerker et al. 2006). 
First of all, an insoluble protein extraction with the homogenate 
of RHO-1 overexpressing worms and a subsequent purification 
of RHO-1 with Nickel-affinity chromatography was performed. A 
well-established elution buffer with a high imidazole concentra-
tion was used. In theory, imidazole competes with the histidine 
tag of the protein for the binding to nickel and therefore lead to 
the elution of the protein that is bound on the column. The first 
purification presented here resulted to a broad elution of RHO-1 
in many fractions. To analyze whether this purification method 
could be used for other proteins, the purification of KIN-19 (a 
serine/threonine kinase orthologous to human Casein Kinase I), 
that is also known to aggregate fast if it is overexpressed in C. 
elegans, was performed. But, as a preliminary result, KIN-19 
could not be eluted from the column (data not shown). Because 
using high imidazole concentrations led to a broad elution of 
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RHO-1 and another protein, KIN-19, could not be eluted, a differ-
ent protocol with harsh conditions was chosen (Tagwerker et al. 
2006). Using the harsh elution buffer, we were able to elute 
RHO-1 in only a few fractions. Next, RHO-1 was chemically cross-
linked with its co-aggregates with the common crosslinker PFA 
(Sutherland, Toews, and Kast 2008) and purified as established 
for RHO-1 without crosslinking under harsh conditions. But the 
following two problems appeared: First, the protein RHO-1 could 
not be eluted from the column anymore. The elution buffer con-
tained EDTA which removes the nickel ions from the column and 
therefore should also remove RHO-1 that was bound with its 
histidine tag to nickel. But in the elution fractions no RHO-1 
could be detected. PFA is a strong crosslinker. Even with low PFA 
amounts it seemed that most of RHO-1 was getting highly insol-
uble and accumulates to big aggregates (together with the co-
aggregates) that stick on the column and cannot be removed. The 
assumed formation of large intractable aggregates could also 
lead to the second problem: a high amount of crosslinked RHO-1 
could not be loaded onto the column because the aggregates 
cannot be disrupted, even with high urea concentrations.  
To continue, the second crosslinker DSG was used, which also 
reacts with primary amines like PFA, but the results could not be 
improved. Still, we were not able to elute RHO-1 from the col-
umn or to get more RHO-1 aggregates solved before loading it 
onto the column. Additionally, lower DSG concentrations were 
used, but no crosslinking could be observed anymore.  
To conclude, the demonstrated purification protocol under harsh 
conditions can be used to purify non-crosslinked RHO-1, but the 
protocol is not applicable to crosslinked proteins. For future 
studies the following possibilities are suggested: First, another 
crosslinker could be tried out that is reactive to different groups 
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compared to PFA or DSG, for example Bis(maleimido)hexane 
(BMH) that crosslinks sulfhydryl groups. Second, to avoid unspe-
cific crosslinking, the pellet after removal of detergent-soluble 
proteins could be diluted in a low amount of urea (1 M) before 
crosslinking and then the crosslinked proteins are solubilized 
with the high amount of urea (8 M). Another possibility is to 
perform the crosslinking already with the detergent-soluble 
proteins. This could help to avoid the formation of huge cross-
linked aggregates that cannot be disrupted by urea anymore.   
(Ayyadevara et al. 2015) isolated and characterized protein 
components of Q40 aggregates using a C. elegans strain express-
ing Q40 as a model of polyglutamine array diseases such as Hun-
tington’s. They found three Q40-associated proteins that were 
inferred to promote aggregation. The knockdown of one of these 
proteins, CRAM-1, reduced the Q40 aggregates up to 86%. Re-
cently, it was shown that a knockdown of six human muscle-
aggregate orthologs, that significantly decreased protein aggre-
gate counts of Q40 and increased muscle mass, also consistently 
rescued worms from amyloid paralysis (Ayyadevara, 
Balasubramaniam, Suri, et al. 2016). (Fonte et al. 2002) used C. 
elegans expressing human Aβ to identify proteins that interact 
with intracellular Aβ and demonstrated that one of these pro-
teins, HSP-16, co-localizes with Aβ. If co-aggregating proteins of 
RHO-1 were successfully identified it would be possible to over-
express RHO-1 together with an interesting candidate in C. ele-
gans and evaluate co-localization or changes in their aggregation 
pattern. Moreover, lifespan analysis can be performed with 
worms overexpressing a rapidly-aggregating protein or with 
worms subjected to RNAi against a rapidly-aggregating protein 
to investigate whether a decrease or an increase in lifespan could 
be observed. Then, this protein (for example RHO-1) would be a 
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candidate for a dangerous aggregating protein that could lead to 
the aggregation of other proteins.  
After the establishment, the protocol could be used to analyse 
whether early-aggregating proteins, identified in 3.1.3, lead to 
aggregation of other proteins. Co-aggregating proteins from 
young and aged worms could be compared by the quantification 
of differences in co-aggregation with age with mass spectrome-
try. Because we recently showed that KIN-19 accelerates PAB-1 
(polyadenylate-binding protein 1) aggregation in C. elegans and 
that both proteins co-localize in large aggregates in double-
transgenic animals (Lechler et al. 2017), we think that co-
aggregation and seeding of protein aggregation by inherent-
aggregating proteins can occur with age. Our goal is to discover 
proteins that lead to further aggregation as a reason for cellular 
dysfunction during aging. This investigation would give insights 
into the general mechanisms of protein aggregation with age and 
therefore could help to understand better the mechanisms in-
volved in neurodegenerative diseases.  
 
In conclusion, the results of both studies presented in this thesis 
help to advance our understanding of aging in the absence of 
disease. Moreover, the first study helps to understand the influ-
ence of aging on pathophysiology. How age-dependent protein 
aggregation and disease-associated protein aggregation influ-
ence each other, is still an open question. The first study sup-
ports the hypothesis of a direct interaction whereby disease-
associated proteins and age-dependent aggregation-prone pro-
teins co-aggregate. We were able to show that misfolded pro-
teins aggregating with age form heterologous seeds that initiate 
Aβ aggregation in vitro. As a prevention strategy, heterologous 
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seeds could be targeted before the onset of the disease. In gen-
eral, the investigation of physiological age-dependent protein 
aggregation could give insights into molecular and cellular 
mechanisms that regulate protein aggregation and could help to 
understand the effect of protein insolubility on organisms health.  
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6 Appendix 
6.1 Abbreviations 
Aβ Amyloid-beta 
AD Alzheimer’s disease 
APP Amyloid precursor protein 
APS Ammonium persulfate 
BMH Bis(maleimido)hexane 
BSA Bovine serum albumin 
CaCl2 Calcium chloride 
C. elegans Caenorhabditis elegans 
CV Column volume 
Da Dalton 
DSG Disuccinimidyl glutarate 
dsRNA Double-stranded RNA 
DTT Dithiothreitol 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethyleneglycoltetraacetic acid 
ER Endoplasmic reticulum 
FDR False discovery rate 
FRANK Fibrillization of Recombinant Aβ Nucleation Kinetic 
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GFP Green fluorescent protein 
HCD Higher energy collision dissociation 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGM High Growth Medium 
HRP Horseradish peroxidase 
HSP Heat-shock protein 
iTRAQ isobaric tags for relative and absolute quantitation 
K114 (trans,trans)-1-bromo-2,5-bis-(4-hydroxy) 
styrylbenzene 
LB Lysogeny broth 
LC Liquid chromatography 
MES 4-Morpholineethanesulfonic acid 
mRNA Messenger RNA 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
NaCl Sodium chloride 
NaF Sodium fluoride 
NG Nematode growth  
NP40 Nonidet P40 
N2 Wild-type C. elegans strain 
PBS Phosphate-buffered saline 
PEP Posterior error probability 
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PFA Para-Formaldehyde 
PMSF Phenylmethylsulfonyl fluoride 
PrPSc Scrapie prion protein 
PS-1, -2 Presenilin-1, -2 
PVDF Polyvinylidene difluoride 
RAB Reassembly 
RFP Red fluorescent protein 
RIPA Radioimmunoprecipitation assay 
RNA Ribonucleic acid 
RNAi RNA interference 
rpm rounds per minute 
SAM Significant Analysis of Microarrays 
SDO Sodium deoxycholate 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
TBS Tris-buffered saline 
TBST TBS with 0.1% Tween20 
TDP-43 Transactive response (TAR) DNA-binding protein 
43 
TEMED Tetramethylethylenediamine 
ThT Thioflavin T 
Tris Tris(hydroxymethyl)aminomethane 
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UPR Unfolded protein response 
x g times gravity 
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6.2 Motility analysis 
6.2.1 Settings for The Parallel Worm Tracker software 
Settings were obtained from Dr. Jan Kubanek (Stanford Universi-
ty, USA). 
 
6.2.1.1 Settings to track worm videos with MATLAB R2015b 
 
%open 
outmovie = sprintf('tracked.mp4'); 
MovieOutObj = VideoWriter(outmovie, 'MPEG-4'); Mov-
ieOutObj.FrameRate = framerate; open(MovieOutObj); 
 
%read 
hasFrame(MovieObj); %touch the frame pointer MovieFrame = 
readFrame(MovieObj); 
 
%write 
framepar.resolution = [RES_H, RES_V]; 
frame = fig2frame(gcf, framepar); 
writeVideo(MovieOutObj, frame); 
 
%close 
close(MovieOutObj); 
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6.2.1.2 Settings to analyze videos taken for other time periods 
than 30 s 
 
function TrackWorms() 
 
% 2015-05-04    Updated to accept movie formats beyond .avi, 
using 
% VideoReader (introduced in R2010b) 
% Author: Jan Kubanek (kubanek@go.wustl.edu) 
 
recordbw = 0; %whether to record the video as bw instead of 
gray 
 
WormTrackerPrefs.MinWormArea = 300; 
WormTrackerPrefs.MaxWormArea = 2000; 
WormTrackerPrefs.MaxDistance = 50; 
WormTrackerPrefs.SizeChangeThreshold = 500; 
WormTrackerPrefs.MinTrackLength = 100; 
WormTrackerPrefs.AutoThreshold = 1; 
WormTrackerPrefs.ManualSetLevel = 0.5; 
WormTrackerPrefs.DarkObjects = 0; 
WormTrackerPrefs.PlotRGB = 0; 
WormTrackerPrefs.PauseDuringPlot = 0; 
WormTrackerPrefs.PlotObjectSizeHistogram = 0; 
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% WormTrackerPrefs.CorrectFactor = 0.3; 
WormTrackerPrefs.CorrectFactor = 0.09; 
%image resolution 
RES_H = 2048; 
RES_V = 1536; 
framerate = 20; %fps 
NumberOfFrames = 139; %total number of video frames 
 
%--------------------- 
%clipping 
 
%clip to a rectangle; no clip if empty 
rectangularclip = []; 
%   rectangularclip = [20,310,180,480]; 
 
%clip to a circle; no clip if empty 
 
%focus 2015-10-05 nobact 
%focuspar = [310, 130, 6]; 
 
%2015-10-12 
focuspar = [220, -40, 7]; 
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center_x = RES_H / 2 - focuspar(1); 
center_y = RES_V / 2 - focuspar(2); 
radius = RES_V / focuspar(3); 
circularclip = [center_x, center_y, radius]; %center_x, center_y, 
radius 
%     circularclip = []; % 
 
% Setup figure for plotting tracker results 
% ----------------------------------------- 
WTFigH = findobj('Tag', 'WTFIG'); 
if isempty(WTFigH) 
    WTFigH = figure('Name', 'Tracking Results', ... 
        'NumberTitle', 'off', ... 
        'Tag', 'WTFIG'); 
else 
    figure(WTFigH); 
end 
 
%settings for movie output 
% axis tight; 
% set(gca,'nextplot','replacechildren'); 
% set(gcf,'Renderer','zbuffer'); 
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% Start Tracker 
% ------------- 
for MN = 1, %for all movies 
     
%     MovieObj = VideoReader(MovieNames{MN}); 
    Tracks = []; 
     
    % can use the information if necessary 
%     NumberOfFrames = MovieObj.NumberOfFrames; 
     
    %initiate video output 
    %can use the following R2014b+ (see more comments on that 
below) 
%     outmovie = sprintf('tracked.mp4'); 
%     MovieOutObj = VideoWriter(outmovie, 'MPEG-4'); 
%     MovieOutObj.FrameRate = framerate; 
%     open(MovieOutObj); 
 
    %in R2015a, use avifile 
    hFig = figure('Visible','off'); 
    set(hFig, 'PaperPositionMode','auto', 'InvertHardCopy','off') 
    aviobj = avifile('tracked.avi', 'fps', framerate); 
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    %   if circular clipping, precompute the clip area (use it as a 
multiplication mask) 
    if ~isempty(circularclip), 
        cx = round(circularclip(1)); 
        cy = round(circularclip(2)); 
        ra = round(circularclip(3)); 
         
%         MovieFrame = read(MovieObj, 1); %if read() is still sup-
ported (R2014a doensn't have readFrame yet) 
         
        SX = RES_H; 
        SY = RES_V; 
         
        mask = ones(SY, SX, 1); 
        for xx = 1 : SX 
            for yy = 1 : SY 
                if (xx - cx)^2 + (yy - cy)^2 > ra^2, %outside the circle 
                    mask(yy, xx, :) = 0; 
                end 
            end 
        end 
        mask = uint8(mask); 
    end     
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    % Analyze Movie 
    % ------------- 
    firstframe = 1; 
    for frameno = firstframe : NumberOfFrames, 
        fprintf('Processing frame no %d\n', frameno); 
         
        try 
%             MovieFrame = read(MovieObj, frameno); %if read() is 
still supported (R2014a doensn't have readFrame yet) 
            MovieFrame = imread(sprintf('Image_%d.bmp', frame-
no)); 
        catch 
            hasFrame(MovieObj); %touch the frame pointer 
            MovieFrame = readFrame(MovieObj); %if read is no more 
supported, readFrame will (readFrame doesn't need the frameno 
argument; it just reads the next frameno; haven't tested though!) 
        end 
         
        if ~isempty(rectangularclip), 
            MovieFrame = MovieFrame(rectangularclip(1) : rectangu-
larclip(2), rectangularclip(3) : rectangularclip(4), :); 
        end 
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        %record the stimulus (LED at the very edge of the image) 
        stimval = double(MovieFrame(end, end, :)); 
         
        if ~isempty(circularclip), 
            %apply the circular mask 
            MovieFrame = MovieFrame .* mask; 
             
            %reduce the size 
            MovieFrame = MovieFrame(cy - ra : cy + ra, cx - ra : cx + ra, 
:); 
        end 
%         [a, MSGID] = lastwarn(); 
%         warning('off', MSGID); 
                 
        if frameno == firstframe, 
            figure; 
            imshow(MovieFrame); 
%             pause; 
        end 
         
        % Convert frame to a binary image 
        if WormTrackerPrefs.AutoThreshold       % use auto thresh-
olding 
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            Level = graythresh(MovieFrame) + WormTracker-
Prefs.CorrectFactor; 
            Level = max(min(Level,1) ,0); 
        else 
            Level = WormTrackerPrefs.ManualSetLevel; 
        end 
        if WormTrackerPrefs.DarkObjects 
            BW = ~im2bw(MovieFrame, Level);  % For tracking dark 
objects on a bright background 
        else 
            BW = im2bw(MovieFrame, Level);  % For tracking bright 
objects on a dark background 
        end 
         
        % Identify all objects 
        [L,NUM] = bwlabel(BW); 
        STATS = regionprops(L, {'Area', 'Centroid', 'FilledArea', 'Ec-
centricity'}); 
         
        % Identify all worms by size, get their centroid coordinates 
        WormIndices = find([STATS.Area] > WormTracker-
Prefs.MinWormArea & ... 
            [STATS.Area] < WormTrackerPrefs.MaxWormArea); 
        NumWorms = length(WormIndices); 
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        WormCentroids = [STATS(WormIndices).Centroid]; 
        WormCoordinates = [WormCentroids(1:2:2*NumWorms)', 
WormCentroids(2:2:2*NumWorms)']; 
        WormSizes = [STATS(WormIndices).Area]; 
        WormFilledAreas = [STATS(WormIndices).FilledArea]; 
        WormEccentricities = [STATS(WormIndices).Eccentricity]; 
         
        % Track worms 
        % ----------- 
        if ~isempty(Tracks) 
            ActiveTracks = find([Tracks.Active]); 
        else 
            ActiveTracks = []; 
        end 
         
        % Update active tracks with new coordinates 
        for i = 1:length(ActiveTracks) 
            Tracks(ActiveTracks(i)).Stimulus = 
[Tracks(ActiveTracks(i)).Stimulus; stimval]; 
            DistanceX = WormCoordinates(:,1) - 
Tracks(ActiveTracks(i)).LastCoordinates(1); 
            DistanceY = WormCoordinates(:,2) - 
Tracks(ActiveTracks(i)).LastCoordinates(2); 
            Distance = sqrt(DistanceX.^2 + DistanceY.^2); 
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            [MinVal, MinIndex] = min(Distance); 
            if (MinVal <= WormTrackerPrefs.MaxDistance) & ... 
                    (abs(WormSizes(MinIndex) - 
Tracks(ActiveTracks(i)).LastSize) < WormTracker-
Prefs.SizeChangeThreshold) 
                Tracks(ActiveTracks(i)).Path = 
[Tracks(ActiveTracks(i)).Path; WormCoordinates(MinIndex, :)]; 
                Tracks(ActiveTracks(i)).LastCoordinates = WormCoor-
dinates(MinIndex, :); 
                Tracks(ActiveTracks(i)).Frames = 
[Tracks(ActiveTracks(i)).Frames, frameno]; 
                Tracks(ActiveTracks(i)).Size = 
[Tracks(ActiveTracks(i)).Size, WormSizes(MinIndex)]; 
                Tracks(ActiveTracks(i)).LastSize = 
WormSizes(MinIndex); 
                Tracks(ActiveTracks(i)).FilledArea = 
[Tracks(ActiveTracks(i)).FilledArea, WormFilledAre-
as(MinIndex)]; 
                Tracks(ActiveTracks(i)).Eccentricity = 
[Tracks(ActiveTracks(i)).Eccentricity, WormEccentrici-
ties(MinIndex)]; 
                WormCoordinates(MinIndex,:) = []; 
                WormSizes(MinIndex) = []; 
                WormFilledAreas(MinIndex) = []; 
                WormEccentricities(MinIndex) = []; 
            else 
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                Tracks(ActiveTracks(i)).Active = 0; 
                if length(Tracks(ActiveTracks(i)).Frames) < 
WormTrackerPrefs.MinTrackLength 
                    Tracks(ActiveTracks(i)) = []; 
                    ActiveTracks = ActiveTracks - 1; 
                end 
            end 
        end 
         
        % Start new tracks for coordinates not assigned to existing 
tracks 
        NumTracks = length(Tracks); 
        for i = 1:length(WormCoordinates(:,1)) 
            Index = NumTracks + i; 
            Tracks(Index).Active = 1; 
            Tracks(Index).Path = WormCoordinates(i,:); 
            Tracks(Index).LastCoordinates = WormCoordinates(i,:); 
            Tracks(Index).Frames = frameno; 
            Tracks(Index).Size = WormSizes(i); 
            Tracks(Index).LastSize = WormSizes(i); 
            Tracks(Index).FilledArea = WormFilledAreas(i); 
            Tracks(Index).Eccentricity = WormEccentricities(i); 
            Tracks(Index).Stimulus = double(0.0); 
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        end 
         
        % Display every FrameRate'th frame 
        if ~mod(frameno, 1) 
            if recordbw, 
                mov.cdata = BW; 
                mov.colormap = []; 
            else 
                mov.cdata = MovieFrame; 
                mov.colormap = colormap; 
            end                 
            PlotFrame(WTFigH, mov, Tracks); 
            FigureName = sprintf('Tracking Results for frame %d   ', 
frameno); 
            set(WTFigH, 'Name', FigureName); 
             
            if WormTrackerPrefs.PlotRGB 
                RGB = label2rgb(L, @jet, 'k'); 
                figure(6) 
                set(6, 'Name', FigureName); 
                imshow(RGB); 
                hold on 
                if ~isempty(Tracks) 
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                    ActiveTracks = find([Tracks.Active]); 
                else 
                    ActiveTracks = []; 
                end 
                for i = 1:length(ActiveTracks) 
                    plot(Tracks(ActiveTracks(i)).LastCoordinates(1), ... 
                        Tracks(ActiveTracks(i)).LastCoordinates(2), 'wo'); 
                end 
                hold off 
            end 
             
            if WormTrackerPrefs.PlotObjectSizeHistogram 
                figure(7) 
                hist([STATS.Area],300) 
                set(7, 'Name', FigureName); 
                title('Histogram of Object Sizes Identified by Tracker') 
                xlabel('Object Size (pixels') 
                ylabel('Number of Occurrences') 
            end 
             
            if WormTrackerPrefs.PauseDuringPlot 
                pause; 
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            end 
             
            %write frame to video 
            %frame = getframe(gcf); %getframe sucks, capture any-
thing 
            %that's on the screen 
             
            %the following is an alternative to getframe, but only 
works in 
            %R2014b+; But R2015b has issue with exporting eps (ex-
ports triangular objects) so not using it; 
            %try to see whether R2015 fixes that; in that case, can use 
the 
            %following code: 
%             framepar.resolution = [RES_H, RES_V]; 
%             [frame] = fig2frame(gcf, framepar); 
%             writeVideo(MovieOutObj,frame); 
 
%so for now, use the deprecated avifile (may slow things down) 
            aviobj = addframe(aviobj, gcf); 
        end 
         
    end    % END for frameno = 1:MovieObj.NumFrames 
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    %save the video 
    %use in R2014b+ 
    %close(MovieOutObj); 
    %for the moment (R2014a), use: 
    aviobj = close(aviobj); 
     
    % Get rid of invalid tracks 
    DeleteTracks = []; 
    for i = 1:length(Tracks) 
        if length(Tracks(i).Frames) < WormTracker-
Prefs.MinTrackLength 
            DeleteTracks = [DeleteTracks, i]; 
        end 
    end 
    Tracks(DeleteTracks) = []; 
     
    % Save Tracks 
    SaveFileName = sprintf('wormcords.mat'); 
    save(SaveFileName, 'Tracks'); 
     
    close all; %close fig 
end 
 
Appendix 
 
137 
 
6.2.2 Motility analysis of Aβ overexpressing C. elegans sub-
jected to control RNAi 
Table 6.1: Motility analysis of Aβ overexpressing worms subjected to dif-
ferent control RNAi’s (L4440, HER-1, GFP). Shown are the speeds of the 
worms (mm/s) after analysis with MatLab or ImageJ. For both analysis 
programs the minimum speed is highlighted in red and the maximum 
speed is highlighted in green. The average speed is shown bold.   
L4440 HER-1 GFP 
MatLab ImageJ MatLab ImageJ MatLab ImageJ 
0.014846 
0.012329 
0.012123 
0.010499 
0.0097831 
0.021533333 
0.0175 
0.019875 
0.016647059 
0.012866667 
0.0056622 
0.0061692 
0.0050093 
0.0050337 
0.0067667 
0.011294118 
0.011470588 
0.0094 
0.010111111 
0.011166667 
0.014553 
0.015467 
0.010147 
0.010635 
0.011438 
0.021375 
0.030636364 
0.013 
0.017555556 
0.0305 
0.01975 
0.0154 
0.011947 
0.011763 
0.0089456 
0.038157895 
0.0331 
0.021 
0.023 
0.019263158 
0.022927 
0.0055339 
0.0051462 
0.022897 
0.022708 
0.06325 
0.0269 
0.025777778 
0.028071429 
0.0314 
0.0069989 
0.0057541 
0.0057969 
0.0057378 
0.0058266 
0.013928571 
0.0124 
0.012833333 
0.012153846 
0.011923077 
0.020185 
0.010325 
0.011594 
0.010209 
0.010137 
0.0288125 
0.0228125 
0.019625 
0.0153125 
0.01475 
0.024152 
0.010978 
0.037393 
0.014137 
0.018501 
0.0481 
0.042642857 
0.0495 
0.03625 
0.017785714 
0.015416 
0.0084805 
0.010284 
0.010398 
0.0079139 
0.023166667 
0.02 
0.0151 
0.016125 
0.013125 
0.012656 0.0202625 0.014201 0.027320994 0.0096564 0.017588161 
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6.3 Statement of contributions 
All experiments and data analyses described for the first project 
with the title "Identifying age-dependent heterologous seeds for 
amyloid-β aggregation" were performed by myself besides the 
ones that are listed in the next paragraph. Briefly, I performed 
the following experiments and analyses: strain generation of 
DCD296, C. elegans liquid culture, insoluble protein extraction 
and quick protein extraction, gel electrophoresis and western 
blotting, mass spectrometry analysis with C. elegans samples 
(dialysis, preparation, labeling), mass spectrometry analysis 
with mice samples (dialysis and data analysis), motility analysis, 
paralysis assay and staining of C. elegans with K114. 
Anika Bühler performed the FRANK Assay, in detail the prepara-
tion of the Assay plate and the measurements, supervised by Dr. 
Frank Baumann who also evaluated the data. Both worked at the 
Hertie Institute for Clinical Brain Research, Tübingen. For the 
FRANK assay, the peptide Aβ(1-40) was expressed and purified 
by Prof. Marcus Fändrich (University Ulm). Dr. Frank Baumann 
removed the mouse brains for the FRANK Assay or mass spec-
trometry analysis. The intracerebral injection into APP23 trans-
genic mice and analysis were performed by Ulrike Obermüller 
and supervised by Dr. Frank Baumann (Hertie Institute for Clini-
cal Brain Research, Tübingen). Mass spectrometry and data 
analysis with samples from C. elegans were performed by Dr. Ka 
Wan Li, Pim van Nierop and Prof. August B. Smit (VU University 
Amsterdam). Mass spectrometry analysis with mice samples, in 
detail the labeling of the samples and nano-liquid chromatog-
raphy-MS/MS analysis, were performed by Dr. Ana Velic (Prote-
ome Center Tübingen). The Ingenuity Pathway Analysis was 
performed by Dr. Chaolie Huang (DZNE, Tübingen). The intern 
Stavros Vagionitis performed the motility analysis after knock-
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down of early-aggregating proteins that continued to aggregate 
strongly at day 10 and day 14 (DZNE, Tübingen). To be able to 
use the Parallel Worm Tracker software changes were made in 
the MATLAB code by Björn Müller (CIN, Tübingen) and Angelos 
Skodras (DZNE, Tübingen). 
The following colleagues contributed to the second project de-
scribed in this thesis with the title "Investigation whether rapid-
ly-aggregating proteins seed the aggregation of other proteins":  
Dr. Emily Crawford developed the tandem-affinity purification 
strategy and generated a Gateway vector with histidine-avidin 
tag. Katja Widmaier performed the construct injection into N2 
animals to generate the transgenic C. elegans line used for the 
project. Both worked at the DZNE, Tübingen. 
All other experiments and data analyses described for the second 
project were performed by myself. Briefly, I performed the clon-
ing and strain generation (besides the construct injection), 
C. elegans liquid culture, insoluble protein extraction with and 
without chemical crosslinking, protein purification with nickel 
affinity chromatography, gel electrophoresis and western blot-
ting.   
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